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ABSTRACT
Neurons are particularly vulnerable to hypoxic-ischaemic injury and this injury
which occurs in human brain can lead to death and long-term disability in
survivors. At the cellular level, such events can result in the activation of a number
of pathways such as PI3K/Akt and ERK that can protect neurons from subsequent
insults; some of these effects require changes in gene expression. One possible
neuroprotective strategy against the neuronal damage associated with
hypoxia-ischaemia is to identify and augment these protective changes in gene
expression.
Glucocorticoid hormones are potent regulators of neuronal viability with actions
via both glucocorticoid (GR) and mineralocorticoid receptors (MR). While GR
signalling is known to endanger neurons by making them more vulnerable to the
toxic effects of various insults, predominant MR activation is thought to promote
neuronal survival. Recently MR expression has been shown to be rapidly
increased in response to different types of injury both in vitro and in vivo and this
is associated with enhanced survival, suggesting a novel endogenous survival
mechanism. A causal link between increased MR expression and neuroprotection
has since been demonstrated following transgenic MR overexpression both in
vitro and in vivo, suggesting that increasing MR signalling may have important
therapeutic uses in patients at high risk of hypoxic-ischaemic insults.
This study has aimed to increase our knowledge of the mechanisms underlying the
transcriptional regulation of MR. The rat MR gene gives rise, through alternative
splicing, to three distinct MR mRNA transcripts (MRa, (3 and y) which differ in
their 5'-untranslated regions; each 5'-flanking region operates as a functional
promoter. While MR mRNA egression is known to be modulated through
autoregulation and some compounds such as serotonin and progesterone, the
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mechanism(s) by which injury-induced MR occurs and whether there is
differential regulation of the transcripts is not known.
Transcription of each MR variant was measured in various in vitro models of cell
injury at both the promoter and mRNA level. The results at promoter level suggest
that MRa and MRfl variants are responsive to some but not all types of cell injury
while MRy appears to be unaffected under any condition in neuronal-like cells.
Measurement of mRNA abundance in primary cortical culture subjected to the
same cellular stressors identifies only MR(3 is the primary splice variant.
The abundance of each brain MR variant was also measured in an in vivo injury
model of hypothermic anoxic injury in neonatal rats where damage occurs
predominantly in the hippocampus - the region with the highest expression of MR.
Levels of total MR mRNA were significantly increased in all regions of the
hippocampus under hypothermic conditions (except CA2) and further increased in
the presence of anoxia, which is contributed by MRfl solely. These observations
corroborate the in vitro data in demonstrating a key role for the MR(3 variant in
response to ischaemic injury and support the hypothesis that some of
neuroprotective effects of hypothermia are mediated via MR.
Overall, the data suggests that increased MR expression is not a generic response
to injury and that there is indeed differential regulation of the transcripts
depending on the type of injury, which exclusively via the expression of MR(3.
This provides a greater understanding of the regulation of MR in the context of
brain cell injury and should contribute to the future clinical exploitation of the




Men ought to know that from nothing else but the brain come joys, delights,
laughter and sports, and sorrows, griefs, despondency, and lamentations. And by
this, in an especial manner, we acquire wisdom and knowledge, and see and hear
and know what are foul and what are fair, what are bad and what are good, what
are sweet and what are unsavory
Hippocrates, On the SacredDisease (4th century B.C.)
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1.1 The structure and function of the brain
Perhaps the most sophisticated organ in humans is the brain - the control centre of
the body - which regulates the flow of information to receive and act with speed
in a coordinated manner in response to internal or external stimuli. This includes
involuntary reactions such as breathing, digestion and heart beat, and voluntary
actions, such as talking and walking. In particular, the brain is the seat for
intelligence that distinguishes human beings from other mammalian animals.
The human brain is composed of four principle sections: the cerebrum,
diencephalon, cerebellum and brain stem. The cerebrum is the largest and most
well-developed section in the mammalian brain, particularly in humans and is
involved in directing movement, sensory processing, and other more complex
functions such as perceptual awareness, emotion, language, learning and memory.
The diencephalon comprises the thalamus and hypothalamus: the thalamus serves
to process all sensory input to the cortex while the hypothalamus exerts control
over the pituitary gland and subsequently the endocrine system. Together the
cerebrum and diencephalon are known as the forebrain. The cerebellum is the
hindbrain structure, which mainly participates in the integration of sensory
perception, coordination and motor control. The brain stem is the conduit for the
major tracts that pass the information on the way to or from the brain. It also plays
a vital role in basic attention and consciousness and is critical for cardiovascular
and respiratory control (Siegel et al. 1998).
1.1.1 Neurons
The brain is largely composed of two broad classes of cell, neurons and glia.
Although neurons are outnumbered by glia by 10-fold, they are the primary
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responsive cells. Like other cells in the body, neurons have common cellular
organelles; for example, nucleus, endoplasmic reticulum, Golgi complexes and
mitochondria, to maintain the normal cellular activities (Siegel et al. 1998). These
are contained in the central part of the neuron called the soma. However, neurons
are highly specialized in that they contain two unique features: axons and
dendrites. Dendrites are cellular extensions of the soma and the sites of input from
neighbouring neurons. Axons are usually a single projection from the soma which
can project up to a thousand times the length of the soma and are responsible for
carrying nerve signals away from the soma to another neuron (Bear et al. 2007).
Neurons process information by conducting electrical impulses through the
movement of electrical charge in the form of chemical ions (Na+, K+, Ca2+ and CI")
across the cell membrane (Siegel et al. 1998). Under resting conditions, neurons
maintain high concentrations of extracellular Na+ and Ca2+ and intracellular K+
through selective ATP-dependent ion channels in the membrane: such as the
Na+-K+ pump and Ca2+ pump (Armstrong 1981; Catterall 1991).
Upon chemical or mechanical stimuli, Na+ channels are opened causing Na+ influx
into the neuron to depolarise the neuron (Armstrong 1981). This has the effect of
opening voltage-gated K+ channels to allow K+ ions to leave the neuron and
depolarise the membrane. This cycle of depolarisation/repolarisation is propagated
along the length of the axon to the terminal where the electrical impulse is
converted to a chemical signal through the release of a specific neurotransmitter




Glial cells are the non-neuron cells of the brain and do not conduct electrical
impulses. However their presence is essential for the proper functioning of the
neurons and they can be sub-divided into macroglia (astrocytes and
oligodendrocytes) and microglia. Overall, glial cells are present in much greater
abundance in the brain and their major function is to provide metabolic support in
the form of nutrient and oxygen supply, maintain homeostasis by regulating the
chemical environment, provide structural support and an immune defence system
(Ransom et al. 2003; Volterra et al. 2005; Haydon el al. 2006).
1.1.3 Metabolic demands of the brain
As a result of a high state of metabolic activity, neurons have a high demand for
energy. Unlike most other organs which are considerably flexible to different
energy substrates, the brain exclusively utilizes glucose and oxygen to meet its
energy demands in the form of ATP production via the mitochondrial respiratory
chain. Approximately 4xl021 molecules (7mmol) of ATP per minute are estimated
to be generated in the entire human brain (Siegel et al. 1998). However this is
consumed almost as quickly as it is generated because the brain is unable to store
ATP. Under normal conditions, a fine balance is struck between the rate of ATP
produced and utilized.
The majority of the ATP is used to power the ion pumps which regulate the ion
flux across the neuronal membrane to form the action potential and therefore
generate electrical conductance. For example, as much as 70% of the ATP is
required by the Na+/K+ pump itself whereas the energy expenditure for protein and
lipid synthesis, turnover of neurotransmitters, aminophospholipid translocation
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and Ca2+ transport accounts for only a few percent (Siegel et al. 1998). Since the
brain relies only on oxygen and glucose as energy substrates, a lack in their supply
such as a reduction of blood flow into the brain can have serious consequences
(Hansen et al. 1988).
1.2 Cerebral isehaemia
1.2.1 Definition
Cerebral ischaemia is a condition in which the whole or some part of the brain
loses the normal function due to lack of glucose and oxygen as a result of reduced
blood flow to the brain. It can be a result of various diseases such as stroke, brain
trauma, epilepsy and cardiac arrest and is the most common cause of neurological
death or disability (Mackay et al. 2004). For example, ischaemic stroke ranks as
the third leading cause of death throughout the world, only behind coronary heart
disease and cancer (Young et al. 1995; Mackay et al. 2004).
1.2.2 Classification
Cerebral ischaemia can be broadly grouped into three categories: global, focal and
diffused hypoxia (Figure 1-1). In scientific research, this classification is also
referred to when generating the animal models in vivo.
Global cerebral ischaemia involves the stoppage of blood supply to most or all of
the brain. It is commonly caused by cardiac arrest, ventricular fibrillation and
coronary artery bypass surgery and results in the neuronal injury to selectively
vulnerable regions of the brain. If global ischemia continued indefinitely, then all
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neurons would die. Several rodent models of global cerebral ischaemia exist,
produced mainly by temporary vessel occlusion of vertebral arteries and/or
common carotids (Traystman 2003). The occlusion time is dependent on the
species but in general 5-20 minutes is most commonly used and ischaemia is
subsequently followed by a period of reperfusion. The levels of ATP fall quickly
during global cerebral ischaemia. For example a 2-minute occlusion results in
more than an 85% reduction in ATP in both the gerbil and rat (Ljunggren et al.
1974; Ekholm et al. 1992) whereas the energy levels are generally restored
quickly once reperfusion occurs (Pulsinelli et al. 1983).
The key feature of global cerebral ischaemia is a substantial delay between the
short insult and neuronal death, which generally happens between 12 hours and
several days after reperfusion (Pulsinelli et al. 1979; Kirino 1982; Pulsinelli et al.
1982). This delayed neuronal death depends on the duration and severity of the
insult and the cell population in the vulnerable regions like pyramidal cells in
hippocampal CA1 subfield (Kirino 1982; Crain et al. 1988).
Focal cerebral ischaemia is defined as the blockage of blood in an artery
supplying a specific region of the brain, which represents a typical clinical
ischaemic stroke. It is generally caused by an embolus from a plaque in a large
artery, or a thrombus in the heart, or a platelet plug formed directly in the affected
artery. In focal ischaemia, the area of the lesion is typically smaller than the entire
distribution of the occluded artery, due to the blood supply from the collateral
circulation at the borders of the region.
Focal cerebral ischaemia in nonhuman primate and rodent models is primarily
generated by occlusion of one major cerebral artery, usually the middle cerebral
artery (Symon 1975; Strong et al. 1983; Ginsberg et al. 1989; Traystman 2003).
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Diffused hypoxia: lack of oxygen
in the brain due to dysfunction of
respiratory system
Focal cerebral ischaemia: loss
of blood in a specific region
due to a clot in the artery
supplying that region
Global cerebral ischaemia: loss
of blood to the whole brain due
to cardiac dysfuntion
Fig 1-1 Classification of cerebral ischaemia. Three types of cerebral
ischaemia are broadly present: global, focal cerebral ischaemia and
diffused hypoxia.
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Therefore the damage is caused selectively to the striatum and cortex which are
the main regions fed by the middle cerebral artery. Focal cerebral ischaemia
models can either be temporary or permanent and both types have been used
extensively because the subsequent pathology is highly relevant to human
ischaemic stroke (Traystman 2003). The unique feature of this type of ischaemia is
the formation of an 'ischaemic core', where affected neurons die within seconds to
minutes (Siesjo 1992; Lipton 1999). However, neurons around the rim of the core,
termed as the "penumbra", are damaged and can take up to a few days to die
therefore potentially penumbral neurons can be rescued (Lipton 1999). The extent
of the ischaemic core and penumbra is determined by the duration and the degree
of vascular occlusion (Greenfield et al. 2002) and these parameters can be easily
manipulated in the animal models.
Focal cerebral ischaemia causes a rapid and extensive depletion of ATP levels
down to 25% or less in the core between 5-minute to 4-hour occlusion (Welsh et al.
1991; Folbergrova et al. 1992; Folbergrova et al. 1995). However, levels of ATP in
the penumbra drop less rapidly, generally down to 50-70% after 1-hour ischaemia
(Welsh et al. 1991; Folbergrova et al. 1995; Sun et al. 1995). In temporary focal
ischaemic models where reperfusion occurs, ATP levels are rarely back to normal
pre-ischaemic values (Ikonomidou et al. 1989; Kleiman et al. 1990; Lipton 1999).
Ccerebral hypoxia refers to oxygen deprivation to the brain. Mild or moderate
hypoxia is known as diffused cerebral hypoxia which can be caused by airway
obstruction, pulmonary oedema, altitude sickness or severe anaemia whereas total
deprivation of oxygen is more commonly referred to cerebral anoxia. Hypoxia has
been most widely used in neonatal animals that reliably survive for days after
exposure to such insult, to mimick major forms of neonatal metabolic brain
damage (Vannucci 1990) and for the majority, the oxygen level is generally
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lowered to 8% or even less (Rice et al. 1981; Roohey et al. 1997). Hypoxia
normally induces cerebral dysfunction rather than irreversible damage. However,
similar to global and focal cerebral ischaemia, neuronal fate is determined by the
period of exposure and the severity of the insult for instance in young rats. 60
minutes of hypoxia at 8% oxygen level has been shown to reduce ATP levels by
30-50% (Williams et al. 1994). Much like global cerebral ischaemia, 15-30
minutes of hypoxia at 3% caused early ischaemic cell change and delayed
neuronal loss in CA1 to CA3, striatum and layer 5 of cortex in adults (Salford et al.
1973).
1.2.3 Molecular pathophysiology of cerebral ischaemia
The critical step in cerebral ischaemia is the reduction of ATP levels which leads
to a cascade of cellular events that eventually cause neuronal dysfunction and if
severe, neuronal death. Using different in vitro and in vivo models, the
pathophysiology of ischaemic neuronal death has been largely identified at
cellular and molecular levels.
1.2.3.1 Ion disturbance
Loss of ATP primarily affects the function of the ion pumps; for example, Na+-K+
ATPase. Failure of Na+-K+ ATPase allows the high concentrations of intracellular
Na+, a state opposite to the normal physiological condition, inducing a




Physiological extracellular concentrations of Ca are several thousand times
9+ •
higher than intracellular concentrations and Ca enters the cells mainly via two
types of channels: voltage-controlled and receptor-operated Ca2+ channels (Miller
1987). The export of Ca2+ depends on the ATP directly (ATP-dependent Ca2+
channel) or indirectly (Na+-Ca2+ exchanger) (Baudry et al. 1981).
During ischaemia, intracellular concentration of Ca2+ is significantly increased,
which is contributed by several major factors:
(i) Accumulated Na+ inside the cells due to inhibition of Na+-K+ pump
significantly exchanges more Ca2+ from extracellular environment (Carini
etal. 1994).
(ii) The depolarisation of the neuronal cell membrane triggers the opening of
voltage-gated Ca2+ channels that allows more Ca2+ influx.
(iii) The combination of ATP breakdown and depolarisation greatly impairs
the reuptake process for neurotransmitter glutamate (Wahl et al. 1994).
This leaves excessive glutamate to long-lasting activation of the
ionotropic NMDA and AMPA/kainite receptors, resulting in a further
energy crisis and longer membrane depolarisation. As the receptor-gated
Ca2+ channel, the activation of NMDA receptor also induces more Ca2+
influx into the cells (Budd 1998).
(iv) The ATP-dependent Ca2+ exporting systems are inactive due to energy
failure, leaving a high concentration of intracellular Ca2+ in the cytoplasm
and other cellular organs, which initiates a number of signalling pathways
leading to cell death.
The consequences of Ca2+ overload are enormous because calcium is a universal







Fig 1-2 Schematic illustration of pathophysiolgoical progress in
ischaemia-induced cell death.
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Breakdown of cell membrane and cytoskeleton
Phospholipases
Phospholipases are a group of enzymes that catalyze the hydrolysis of membrane
phospholipids. The activation of phospholipase A2 is mediated by Ca2+ and
involved in fatty acid synthesis. In global cerebral ischaemia, the expression of
phospholipase A2 was enhanced and followed by an increased level of free fatty
acid (Lauritzen et al. 1994; Chan 1996; Pilitsis et al. 2002). The increased fatty
acid is believed to be substantially neurotoxic and detrimental to the membrane
integrity (Yang et al. 2007).
Endonucleases
Brain ischaemia can cause both non-specific and specific DNA cleavage during
the course of cell death. Although the mechanism of non-specific DNA
degradation it is not clear, evidence has shown that the endonuclease-mediated
specific cleavage was mediated by Ca2+ overload (Tominaga et al. 1992).
Proteases
Calpains are cycteine proteases that widely expressed in cytoskeletal systems and
require Ca2+ for activation (Mellgren 1987). Calpain I was considered as the most
important protease to promote ischaemic-induced cell death, according to previous
studies on its location and role in episode of ischaemic cell death (Kirino et al.
1984; Smith et al. 1984; Hamakubo et al. 1986; Perlmutter et al. 1990).
Nitric oxide
Nitric oxide (NO) is a prominent vascular and neuronal messenger molecule
formed directly from the guanidine nitrogen of L-arginine by nitric oxide synthase
(NOS) (Garthwaite 1991). In the brain, NOS has been identified as a monomer of
150kDa inactive protein at basal Ca2+ concentration, while being activated through
increased Ca2+ level (Bredt et al. 1990). The pathogenic importance of NO is
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reflected in a number of observations that pharmacological inhibitors of inducible
NOS reduce ischaemic damage to the brain because the activation of NOS
produces more toxic NO. Low doses of NOS inhibitor nitroarginine reduce infarct
volume following focal ischaemia in rats (Buisson et al. 1992) and mice
(Nowicki et al. 1991). Transgenic mice lacking expression of neuronal NOS
showed a reduced infarct size following ischaemia (Samdani et al. 1997).
Mitochondrial damage
Mitochondrial damage plays an important role in cell death during cerebral
ischaemia (Kluck et al. 1997; Kroemer et al. 1998). A large body of evidence
suggests mitochondrial Ca2+ accumulation is a major mechanism of mitochondrial
damage and cytotoxicity (Ankarcrona et al. 1995; Schinder et al. 1996). A
decrease in the mitochondrial membrane potential and ATP depletion due to
cytosolic Ca2+ accumulation is initiated as the first event (Dubinsky et al. 1998).
Furthermore, the inhibition of mitochondrial Na+-Ca2+ exchanger, which normally
pumps the excessive Ca2+ from the mitochondria into cytoplasm, enhances this
cellular pathological process (Nicholls et al. 1998). Subsequently, these
pathological changes lead to the breach of mitochondrial permeability.
The mitochondrial permeability transition (MPT) is characterized by a sudden
increase in the permeability of the mitochondrial inner membrane to small ions
and molecules (Haworth et al. 1979; Gunter et al. 1994). It was originally
suggested by Nicholls that phospholipase A2 activation broke down the lipid
backbone of the inner membrane, giving rise to a non-specific increase in
mitochondrial membrane permeability (Nicholls 1985). However, a different
mechanism was presented shortly after, that a prolonged opening of a
proteinaceous pore due to the enhanced affinity to the internal site by
mitochondrial Ca2+ is more relevant for this permeability transition (Bernardi et al.
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1992; Connern et al. 1992; Gunter et al. 1994). Loss of membrane potential can
also increase the MPT pore opening (Petronilli et al. 1994). The assembly of the
MPT pore quickly releases Ca2+ and other molecules from intra-mitochondrial
compartments and subsequently the total collapse of electrical potential difference,
allowing the regulated entry of H+ across the inner mitochondrial membrane that
is essential for respiratory chain reaction. Therefore, ATP production is ceased and
osmotic swelling happens in the mitochondria. In addition, mitochondria damage
can produce large quantities of reactive oxygen radicals (Zamzami et al. 1995).
Protein phosphorylation and gene activation
Ca2+ influx is responsible for the activation of a number of protein kinases such as
protein kinase C (PKC) (Domanska-Janik et al. 1992; Fukunaga et al. 1992),
calcium/calmodulin kinase II (CaMK II) (Aronowski et al. 1992; Chum et al.
1992), cAMP-dependent protein kinase (PKA) (Hu et al. 1994) etc. These protein
kinases lead to the activation of a variety of signalling pathways such as CREB
(Corcoran et al. 2001) and MAPK (Hu et al. 1994) to mediate the downstream
gene expression that can determine the cell fate.
1.2.3.3 Free radicals formation
Free oxygen radicals are molecules that possess an outer electron orbital with a
solitary unpaired electron. They are produced in small quantities during aerobic
metabolism in mitochondria. Superoxide anion radicals (Of") and hydrogen
peroxide (H202) are formed during the mitochondrial electron transport chain and
are extremely toxic to the cells (Siesjo et al. 1989). During ischaemia, insufficient
02 is available to accept the electron from the respiratory chain, resulting in the
excessive production of 02'". More hydroxyl radicals (OH ) may be generated from
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H2O2 by the release of iron from ferritin stores and damaged neurons (Halliwell
1992). Except for hydroxyl radicals, nitric oxide is also another form of oxidative
free radicals.
The major consequence of oxidative free radicals is to damage the cellular
macromolecules. For example, the addition of the free 'radicals' electron to a fatty
acid causes fragmentation of the lipid or alteration of its chemical structure,
known as lipid peroxidation, which acts as one detrimental factor to breakdown
the cell membrane (Halliwell 1992). Besides, the other means by which free
radicals damage the proteins are cross-linking between amino acids, carbonyl
formation and protein denaturation. DNA bases can also be modified by oxidation,
leading to non-specific cleavage and mispairing of purine and pyrimidine during
DNA replication (Cao et al. 1988; Halliwell 1992).
In addition to inducing injury directly to the cells, oxidative free radicals may
indirectly affect several pathological changes; for example, enhancement of
NMDA receptor-mediated excitotoxicity, contribution to initiation and early
signals of apoptotic neuronal death and interaction with other multiple injuries like
inflammation (Siesjo et al. 1989).
1.2.3.4 Inflammatory responses
Inflammatory responses by ischaemia are complex and involve a lot of
inflammatory factors. Evidence showed that a number of inflammatory mediators
are induced by ischaemia in astrocytes, microglia, leukocytes and endothelial cells
as the instant initiator (Rothwell 1997), including cytokines, chemokines and
adhesion molecules (Feuerstein et al. 1998). Cytokines such as TNF-a and IL-1(3
are responsible for the accumulation of inflammatory cells in the injured brain and
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affect the survival of damaged neurons. For example, the recruitment of
leukocytes by TNF-a may promote the infarction size by their toxic by-products
and phagocytic action (del Zoppo et al. 1991; Kochanek et al. 1992).
1.2.3.5 Apoptosis
Neurons that suffer irreversible damage induced by ischaemia will eventually
undergo apoptosis, a process of programmed cell death (Goto et al. 1990), which
minimizes the release of genetic materials and other pro-inflammatory
intracellular constituents (Johnson et al. 1993). Apoptosis is characterized by
apparent morphological changes, including chromosome condensation and
aggregation to the nuclear margin, cell body shrinkage, fragmentation of the
nucleus and cytoplasm into membrane-bound vehicles (Kerr et al. 1972; Wyllie et
al. 1980). It is triggered by a number of cellular cascades, such as free radicals,
mitochondrial damage, phosphorylation of some kinases and intracellular Ca2+.
Release of cytochrome c from damaged mitochondria is an important step on the
progress of ischaemia-induced apoptosis (Fujimura et al. 1998; Sugawara et al.
1999). Upon release, cytochrome c is translocated from mitochondria to
cytoplasmic compartment and activates a number of specific downstream caspases
to trigger apoptosis.
1.2.3.6 Necrosis
It is worth mentioning that neurons in ischemic brain also undergo another form of
cell death termed as necrosis, characterized by loss of membrane integrity,
disruption of intracellular organelles, cellular swelling and lysis (Lipton 1999;
Fujita et al. 2003). Unlike apoptosis, the molecular mechanisms of necrosis still
remain to be fully elucidated, while some evidence has emerged that it is closely
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related to the energy failure or drastic loss of cellular ATP levels (Eguchi et al.
1997; Leist et al. 1997). Necrotic cell death happens predominantly in the
ischemic core of focal cerebral ischemia, in comparison to apoptosis which is
mainly responsible for delayed cell death in focal ischemic penumbra and global
hypoxic/ischemia (Lipton 1999). In addition, necrosis occurs rather quickly within
few seconds to minutes after the onset of ischemia and can not be reversed by any
means insofar (Ueda et al. 2004), therefore it is not discussed in this thesis.
1.2.4 Neuronal survival in cerebral ischaemia
At the same time that cerebral ischaemia triggers the cascade of events that leads
to neuronal death, neurons also mount their own endogenous survival mechanisms
in an attempt to restore homeostasis. Therefore the balance between activation of
death and survival pathways determines the fate of the neuron. For the most part,
activation of endogenous protective mechanisms also requires changes in gene
expression.
1.2.4.1 Endogenous survival factors
Basic fibroblast growth factor
Basic fibroblast growth factor (bFGF) contains a family of growth factors
involved in angiogenesis, wound healing and embryonic development. In the brain,
bFGF is widely expressed in both neurons and glial cells. It has been shown that
expression of bFGF was markedly increased in the hippocampi of rats following
transient global ischaemia (Takami et al. 1992; Endoh et al. 1994). In in vitro rat
hippocampus culture, bFGF pre-treatment promoted long-term survival and
significantly enhanced the resistance of neurons to glutamate and NMDA toxicity
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(Morrison et al. 1986; Mattson et al. 1993), glucose deprivation (Cheng et al.
1991) and hypoxia (Mattson et al. 1993). This neuroprotective effect of bFGF was
also found in in vivo animal models of ischaemia (Nakata et al. 1993; Koketsu et
al. 1994).
Neurotrophins
Neurotrophins (or neurotrophic factors) belong to the family of growth factors.
Due to their specific functions in the brain, in this thesis neurotrophins are listed
as a separate part. In general, neurotrophins include four structure-related proteins,
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5). Each of these
neurotrophins is expressed in the brain in distinct region and cellular patterns. For
example, BDNF is produced in all neuronal cells, while NGF is only expressed at
high level in hippocampal neurons (Hennigan et al. 2007). It is accepted that
neurotrophins mediate the neuronal development and are in trophic support of
adult neurons under normal circumstances. While in brain injuries like ischaemia,
the expression of neurotrophins in particular BDNF and NGF can be increased to
significant levels (Lindvall et al. 1992). The induction of neurotrophins was
followed by the attenuated neuronal loss in various cerebral ischaemia models. For
example, the intraventricular administration of NGF protected hippocampal
neurons against ischaemic injury in rats (Shigeno et al. 1991). NT-3 and BDNF
rescued the hippocampal, septal and cortical neurons against glucose-deprivation
(Cheng et al. 1994). Therefore, the expression of neurotrophins is essential for
rescuing neurons at risk of death.
Hypoxia-inducible factor-1 (HIF-1)
HIF-1 is a transcription factor playing a central role in cellular regulation of a
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broad variety of hypoxia/ischaemia-induced genes (Semenza 1998). In cell
nucleus, HIF-1 binds to specific DNA sequence in enhancers and promoters of the
target genes such as erythropoietin, some glucose transporters, several glycolytic
enzymes and vascular endothelial growth factor (VEGF) (Ebert et al. 1995;
Semenza 1998; Wood et al. 1998). Accumulation of HIF-1 was thought to
contribute to the neuroprotection of the neonatal brain against hypoxia/ischaemia
by adaptation to this insult, such as regulating VEGF (Ikeda et al. 1995; Forsythe
et al. 1996). glucose transport (Gidday et al. 1994) and glycolysis (Wood et al.
1998).
Endogenous inhibitors of apoptosis
Inhibitors of apoptosis proteins (LAPs) are endogenous anti-apoptotic proteins
which potently inhibit prominent caspases (caspase-3, -7 and -9) in apoptotic
pathways mediated by mitochondria. X chromosome-linked inhibitor of apoptosis
protein (XLAP) is a particularly interesting target and has been investigated well in
previous studies. XIAP was found significantly increased in the brain after
hypoxia-ischaemia by cardiac arrest (Katz et al. 2001). Another study showed the
protein level of XIAP was enhanced in the hippocampal homogenate in rats 24
hours following cerebral ischaemia and suggested that as the checkpoint in the
progress of apoptosis (Siegelin et al. 2005). Viral-mediated over-expression of
XIAP in the rat hippocampus prevented CA1 neurons from degeneration after
transient forebrain ischaemia (Xu et al. 1999). Transgenic mice overexpressing
human XIAP in neurons displayed a smaller lesion size, less reduction in protein
synthesis and less active pro-apoptotic caspase-3 after cerebral ischaemia (Trapp
et al. 2003). Therefore, XIAP plays a vital role in mediating apoptosis progress
and it itself is a neuroprotective factor.
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Heat shock protein (HSP)
HSPs are highly conserved molecular chaperones in bacteria, plant and animals
which bind intracellular proteins and prevent their inappropriate folding (Nowak
et al. 1994). The 70kD member of HSP family, HSP70, has received most
attention. Cerebral ischaemia markedly increased the expression of HSP70 in the
neurons (Nowak et al. 1994). Magnetic resonance imaging (MRI) studies
suggested that overexpression of HSP70 reduced overall lesion size and may limit
the tissue damage within the lesion in permanent cerebral ischaemia (van der
Weerd et al. 2005). Conversely, mice lacking the HSP70 gene have increased
infarction and apoptotic cell death in transient focal ischaemia (Lee et al. 2004).
The mechanism of HSP70-induced neuroprotection was widely believed to be its
chaperone activity at first, while new evidence has emerged that HSP70 can also
inhibit the release of cytochrome c from damaged mitochondria (Tsuchiya et al.
2003), sequester the apoptosis-inducing factor (Matsumori et al. 2005) and
modulate the JNK-mediated apoptotic signalling (Meriin et al. 1999; Park et al.
2001).
Anti-apoptotic protein in Bcl-2 family
Bcl-2 family contains a number of intracellular proteins regulating apoptosis and
over 30 members of this family have been identified in higher eukaryotes to date
(Borner 2003). Despite of the controversial points on the mechanisms, many
researchers believe that Bcl-2 family proteins can directly regulate the MPT pore
through which cytochrome c is released (Shi 2001). Anti-apoptotic proteins like
Bcl-2 and Bcl-xL can maintain the mitochondrial membrane potential by MPT
pore and block the cytochrome c release while pro-apoptotic proteins such as Bax,
Bcl-xS, Bak, Bid and Bad function conversely (Merry et al. 1997). Bcl-2 protein
is predominantly located within the intracellular membranes and it protects both
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the neural cell line and primary mouse cortical cultures from apoptotic and
necrotic insults (Kane et al. 1993). Furthermore, overexpression of the Bcl-2 gene
in transgenic mice reduced the infarct volume after focal cerebral ischaemia while
Bcl-2 knockout mice showed the opposite effects in response to the same insult
(Martinou et al. 1994; Hata et al. 1999).
1.2.5 Treatment for cerebral ischaemia
Current clinical treatment for cerebral ischaemia is limited and generally relies on
rehabilitation and palliative care. The only licensed drug by the US Food and Drug
Administration (FDA) for treating cerebral ischaemic patients is recombinant
tissue plasminogen activator (rt-PA), aimed at dissolving the thrombus to allow
restoration of blood flow. Utilization of rt-PA improves outcomes (Hacke et al.
2004) while intravenous administration of rt-PA is only available to a small
proportion of patients, due to the short treatment time window (3 hours after onset
of ischaemia) (The National Institute of Neurological Disorders and Stroke rt-PA
Stroke Study Group 1995), risk of haemorrhage (Warlow et al. 1997) and potential
neurotoxicity (Kaur et al. 2004; Goto et al. 2007).
1.2.5.1 Failed neurprotectants in clinical trials
Gradual unravelling of the ischemic cascades has introduced the concept of
neuroprotection. Based on previous research, blockade of one or more factors in
death pathways, or overwhelming activation of survival pathways can lead to the
protection of neuronal cells from damage or death (Green et al. 2006). The first
strategy has undoubtedly become the priority for the development of
neuroprotectants, for the mechanisms of ischemic cell death in cerebral ischaemia
have now been well elucidated. Therefore, numerous inhibitors or blockers of ion
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channels, antagonists of excitotoxic factors and scavengers of free radicals have
been developed and tested in pre-clinical trials, most of which achieved great
success at various levels from in vitro single cell, cell culture, brain slices to in
vivo animal models (Green et al. 2006; Hossmann 2006). However, these
pre-clinical data are poorly translated into clinical trials. Systematic review on
1026 interventions, which covers a wide range of experimental treatments in acute
stroke, has revealed that only rt-PA, aspirin and stroke unit care are effective in
clinical trials (The National Institute of Neurological Disorders and Stroke rt-PA
Stroke Study Groupl995; International Stroke Trial Collaborative Group 1997;
O'Collins et al. 2006). Clearly, none of these interventions are related to
neuroprotection per se. Whether such neuroprotective drugs exist and can be
useful remains to be identified. There are several reasons to explain the poor
translation of candidate drugs to the clinic implications as highlighted by
systematic review analysis, which include improper experimental design, false
positive results from animal studies and different responses to ischaemia between
animal and human brains (Sena et al. 2007; Shuaib et al. 2008). More importantly,
the strategy based on blocking death signalling requires a closer examination
particularly given the most recent drug failure at clinical trial. NXY-059, a free
radical trapping agent considered to be highly promising and has proved effective
in pre-clinical experiments following all rigorous STAIR (Stroke Therapy
Academic Industry Round Table) criteria (Zhao et al. 2001; Sydserff et al. 2002;
Green et al. 2003; Wang et al. 2004), failed in clinical trials (Shuaib et al. 2007).
This adds more concerns on the strategy for drug development. Table 1 gives
detailed information of some neuroprotective agents in clinical trials and their
outcome illustrates the concern over the effectiveness of so called neuroprotective
drugs for cerebral ischaemia.
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Table 1-1 Summary of failed trials of neuroprotective agents





Blood pressure affects outcome
(Fogelholm et al. 2004)
Fosphenytoin Sodium channel
blocker
Phase III trails failed Lack of efficacy
BMS-204352 Potassium channel
opener
Phase III trails failed
Selfotel NMDA antagonist No efficacy in Phase
III trials
Poorly tolerated with a potential
neurotoxicity
(Davis et al. 2000)
Aptiganel NMDA channel
blocker
No efficacy in Phase
III trials
Potential detrimental effects in
patients
(Albers et al. 2001)




Outcome is worsned Only works in reperfusion model
Lubeluzole Ion channel and
nitric oxide blocker
No efficacy in Phase
III trials
Potential increase in heart
conductance disorders
(Gandolfo et al. 2002)
UK-279,276 Neutrophil
inhibitory factor
Phase III trails failed Only work in reperfusion models
Trafermin Growth factor Phase II/III trails halt Lack of efficacy
Repinotan 5-HTiA receptor
antagonist




analysis of Phase II
This table is modified from. (Beresford et al. 2003; Shuaib et al. 2008)
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1.2.5.2 Hypothermia
Recently the endogenous protective mechanisms have become the central stage in
the research on neuroprotection following cerebral ischaemia (Dimagl et al. 2003).
Boosting such mechanisms provides an alternative strategy for potential
neuroprotectant development.
As a natural mechanism which is exploited by many mammalian species to adapt
to extreme environment, hypothermia is known to be neuroprotective for a long
time. A recent systematic review analysis on animal models of focal cerebral
ischaemia showed that outcome in the hypothermic treatment group was
significantly improved by approximately 30% (van der Worp et al. 2007). The first
attempt to use hypothermia as a clinical treatment was back to 1940s for the
treatment of severe traumatic brain injury (Fay 1959). With accumulated evidence,
hypothermia is evaluated in randomized clinical trials in patients with global
cerebral ischaemia after cardiac arrest (Hypothermia after Cardiac Arrest Study
Group 2002; Bernard et al. 2002) and in infants with hypoxic-ischaemic
encephalopathy (Shankaran et al. 2005), which confirms cooling is indeed
beneficial for the reduction ofmortality and morbidity.
In general, two types of hypothermia have been defined: mild (32~35°C) and
moderate hypothermia (30~33°C) (Gentilello 1995). Previous studies in transient
global ischaemia showed that long-term moderate hypothermia provided sustained
behavioural and histological neuroprotection (Busto et al. 1989; Buchan et al.
1990; Baker et al. 1995), while brief and mild hypothermia only delayed the
neuronal damage (Dietrich et al. 1990). Hypothermia performed soon after the
onset of ischaemia and maintained for an adequate length of time is well known to
be neuroprotective. However, hypothermia delayed up to 2 hours after onset of
focal ischaemia has also shown benefit, provided that it was maintained for at least
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1-3 hours (Young et al. 1983). In transient global ischaemia, mild hypothermia
performed for 3 hours at reperfusion onset was very effective at reducing neuronal
damage 3 days after ischaemia (Dietrich et al. 1990). Although current evidence
suggests a minor delay in hypothermia up to 3 hours is still beneficial for neuronal
survival, it makes sense to begin the hypothermic treatment as soon as possible
after the ischaemic onset. Except for the time-window, the effectiveness is also
largely determined by other factors such as duration and depth of hypothermia,
types and severity of ischaemia.
Although the mechanisms of hypothermia in neuroprotection are not entirely clear,
it has been suggested that they are associated with energy reduction (Williams et
al. 1994), maintenance of blood-brain barrier stability (Jiang et al. 1992),
inhibition of excitotoxic glutamate release (Busto et al. 1989), suppression of free
radical generation (Gordon 2001) and up-regulation of anti-apoptotic genes, such
as Bcl-2 (Zhang et al. 2001) and neurotrophic factors (D'Cruz et al. 2002). In
addition, hypothermia also triggers the endogenous signalling pathways PI3K/Akt
(Zhao et al. 2005) and MAPK (Hicks et al. 2000) during cerebral ischaemia to
affect the downstream gene expressions, altering the balance between survival and
death in cell fate.
However, there are several limitations to the utilization of hypothermia in cerebral
ischaemia. The methods of hypothermia, particularly depth, duration, rewarming
and medications need to be assessed and optimized for individual ischaemic
patient. Therefore it may significantly delay the time of application in clinical
usage. Hypothermia also causes some side-effects in clinical treatment. In 50
prospective patients with cerebral infarction, moderate hypothermia caused
thrombocytopenia (70%), bradycardia (62%) and pneumonia (48%) and 15
patients (30%) died during or after rewarming because of rebound increase in
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intracranial pressure (Schwab et al. 2001). The other side-effects include
thermoregulatory shivering (Frank et al. 1993) , myocardial infarction and
infection (Krieger et al. 2001).
Although much evidence shows that hypothermia is a potent neuroprotectant
against cerebral ischaemia, it is still difficult to deliver clinically. Identifying the
mechanism(s) by which hypothermia exerts its neuroprotective effect and using
this instead may prove a more suitable target for future therapeutic strategies.
1.3 Corticosteroids
Corticosteroid hormones are a class of steroid hormones made in the adrenal gland
which are essential for life and required for several physiological systems in
mammals. Corticosteroids can be subdivided into two groups, glucocorticoids (GC)
and mineralocorticoids. The main naturally occurring GC is Cortisol in humans
and corticosterone in rodents, and the main mineralocorticoid is aldosterone.
Under physiological conditions, the level of GC is approximately three orders of
magnitude higher than the aldosterone.
1.3.1 Function
The primary physiological function of aldosterone is the control of electrolyte
homeostasis and blood pressure. The major site of action is the kidney where
aldosterone promotes renal sodium reabsorption and potassium secretion in the
distal nephron. Other aldosterone targets include the distal colon, salivary and
sweat glands where the primary function is to maintain the electrolyte balance.
One consequence of electrolyte reabsorption is the effect on the blood pressure,
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since the water is reabsorbed thereby the intravascular volume is increased, which
subsequently has an influence on blood pressure. Aldosterone also has actions at
non-mineralocorticoid target tissues including the heart, vascular system and the
brain. Prolonged aldosterone exposure in these systems can have detrimental
consequences promoting vascular remodelling, cardiac fibrosis, and hypertension
(Gomez-Sanchez 2004).
In comparison to aldosterone, GCs has more effects on a wide range of
physiological functions in the body including those required for energy balance
and metabolism, immune function, cardiovascular function, circadian rhythmicity,
growth and development, cognitive processes and the expression of various types
of behaviour. For example, GCs regulate energy storage by participating in
glycogenic and glycolytic pathways (Villar-Palasi et al. 1970; Nyirenda et al.
1998). GCs are also a powerful immunosuppressant, which led to the development
of therapeutic applications for the treatment of asthma (Stellato 2007) and
rheumatoid arthritis (Gaffo et al. 2006). In foetal development, GCs promote the
maturation of the lungs and are involved in the differentiation of neural crest cells
(Anderson 1993; Garbrecht et al. 2006).
A major target of GCs is the central nervous system where they exert a broad
range of effects. The hippocampus, an important region for mood, memory and
behaviour, is one of the primary targets of GC action. Both learning and memory
formation have been demonstrated to be closely associated with GC action (Bohus
et al. 1981; Oitzl et al. 1992; McEwen 2005; de Kloet et al. 2008). GCs are also
involved in the coordination of circadian events as the sleep-awake cycle and food
intake (Dallman et al. 1995; Bradbury et al. 1998). The mechanisms may be due
to the effects of GCs on neurotransmitter systems and neuronal excitability (Joels
1997). In the hippocampus, some of neurotransmitter factors are extremely
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sensitive to the level of circulating GCs, including the excitatory effects evoked by
(3-adrenoceptor activation (Joels et al. 1989), the hyperpolarization mediated by
serotonin-1A receptor (Joels et al. 1991) and the Ca2+ influx by the activation of
voltage-dependent calcium channels (Kerr et al. 1992). Long-term potentiation
(LTP), a prolonged enhancement of synaptic contacts, which is believed to
contribute to learning and memory formation (Lynch 2004), is also affected by
GCs (Kim et al. 2002).
In addition to behavioural effects, GCs are also known to play an important role in
maintaining neuronal integrity, enhancing neurogenesis and regulating neuronal
survival (Sapolsky 1996; Abraham et al. 2006).
1.3.2 Synthesis and regulation of corticosteroids
Endogenous corticosteroids are synthesized in the adrenal cortex from the
common precursor cholesterol through a series of enzymatic reactions. Because of
the wide-ranging actions of GCs, circulating levels must be tightly regulated. The
neuro-endocrine system that controls GC secretion is known as a negative
feedback loop hypothalamus-pituitary-adrenal gland (HPA) axis (Aguilera 1998).
The HPA axis is activated either by a circadian signal or by a stress (either
physical or psychological) stimulus. Neural inputs which perceive these signals
converge at the main HPA axis control centre, the hypothalamus to initiate
secretion. Under non-stress conditions, circulating levels of GCs are released both
in an ultradian and diurnal manner. The circadian rhythm is driven by an
endogenous biological 'clock' in the suprachiasmatic nucleus and the rhythm is set
by recurring daylight and darkness (Takahashi et al. 1982). In mammals, the peak















Fig 1-3. The regulation of GC by a negative feedback loop HPA axis. Stimuli
augment the secretion of CRH/AVP and subsequently ACTH. This induces
GC synthesis, which exerts its biological functions. An increase in
concentrations of GCs executes feedback inhibition on HPA axis in pituitary
and hypothalamus, reducing the synthesis of GC in the adrenal gland to
restore the normal level of circulating GC. Refer to text for details.
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during the rest period.
In response to a stimulus, corticotropin-releasing hormone (CRH) and arginine
vasopressin (AVP) are rapidly released from the parvocellular cells of the
paraventricular (PVN) nucleus of hypothalamus into the portal circulation to target
the anterior pituitary. Here CRH and AVP act synergistically to stimulate the
secretion of stored adrenocorticotropic hormone (ACTH) from corticotropic
pituitary cells into the bloodstream. Circulating ACTH binds to its receptor located
at the cell surface of the adrenal cortex to signal an increase in the synthesis of
GCs from cholesterol. Once synthesized, GCs are immediately released into the
systemic circulation to act throughout the body.
At the same time secreted GCs exert a negative feedback on the HPA axis by
suppressing CRH in the hypothalamus and ACTH in the pituitary (Ma et al. 1997),
to prevent further synthesis of GC in the adrenal gland and restore the normal
basal levels (Dallman 2005). This process is critical, because sustained high level
of GCs causes a series of harmful effects in the body.
1.3.3 Bi-directional effect of GCs on neuronal viability
The maintenance of normal neuronal integrity and function is dependent on
physiological concentrations of GCs (Abraham et al. 1997). Either significantly
reduced or chronically increased GC levels can directly threaten neuronal viability.
For example, a lack of GCs (e.g. following adrenalectomy) results in loss of
granule cells of the hippocampal dentate gyrus (DG) in adult rats by apoptosis
(Sloviter et al. 1989; Sloviter et al. 1993) while overexposure to GCs enhances
neuronal vulnerability to toxic challenge particularly in the pyramidal cells of the
CA3 region of the hippocampus (Landfield et al. 1978; Kerr et al. 1991; Hibberd
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et al. 2000).
It is worth mentioning that aberrant concentrations of GCs do not induce neuronal
apoptosis directly but endanger the cells by enhancing their vulnerability to
neurotoxic insults, such as cerebral ischaemia. It has been shown that elevated
plasma GC concentrations following cerebral ischaemia were associated with
increased morbidity and mortality in humans (Feibel et al. 1977; Olsson 1990;
Fassbender et al. 1994) and increased infarct size in mice (DeVries et al. 2001).
Other evidence from animal models also suggests a link between GC
concentrations and focal cerebral ischaemic outcome, in which the manipulation
of GC levels prior or post-focal cerebral ischaemia affects the infarct size
(Sapolsky et al. 1985; Morse et al. 1990; Rami et al. 1998; DeVries et al. 2001;
May et al. 2002). Similarly, in global cerebral ischaemia models, exposure to high
concentrations of GCs also compromises neuronal viability in the hippocampus
(Kofler et al. 2004; Neigh et al. 2004; Neigh et al. 2005).
The major mechanisms through which GCs endanger neuronal cells in exposure to
toxic insults include inhibition of the uptake of key nutrients such as glucose
(Doyle et al. 1993; Sapolsky 1996), modulation of both excitatory (glutamatergic)
and inhibitory (GABAergic) neurotransmission (Moghaddam et al. 1994;
Abraham et al. 1996) and direct enhancement of intracellular Ca2+ signalling
(Kerr et al. 1989; Joels et al. 1994).
1.4 The corticosteroid receptors
The actions of corticosteroids are mediated via binding to two structurally related
intracellular receptors: the mineralocorticoid (MR) and glucocorticoid receptor
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(GR). Both receptors act as transcriptional factors to alter the transcription of both
overlapping and distinct target genes (Datson et al. 2008).
1.4.1 Distribution
MR and GR differ in their distribution. GR is ubiquitously expressed in almost
every cell in the body. Within the brain, GR has a wide distribution in both
neurons and glia, and is highly expressed in the limbic system, particularly the
hippocampus, hypothalamus, and the supraoptic nucleus (de Kloet et al. 2000).
GR is also present in relatively high concentrations in the ascending
monoaminergic neurons of the brain stem (Kerr et al. 1989; Joels et al. 1994).
Compared to GR, MR has more specific distribution which is generally divided
into epithelial and non-epithelial tissues. In epithelial cells of the kidney, MR
expression is located in the distal convoluted tubules and cortical collecting ducts
(Krozowski et al. 1989; Lombes et al. 1990). It is also found in glomeruli
especially in mesangial cells (Nishiyama et al. 2005) and podocytes (Shibata et al.
2007). MR expression in other epithelial tissues include the distal colon (Pressley
et al. 1975; Lombes et al. 1984; Rafestin-Oblin et al. 1989), lung (Krozowski et al.
1981), salivary glands (Pressley et al. 1975; Lombes et al. 1984; Rafestin-Oblin et
al. 1989), sweat glands (Funder et al. 1972), inner ear (Trune et al. 2006) and skin
(Kenouch et al. 1994).
In non-epithelial tissue, MR is found in mononuclear leucocytes (Armanini et al.
1985), cardiomyocytes of the heart (Bamett et al. 1988) and in both white and
brown adipose tissue (Zennaro et al. 1998; Caprio et al. 2007). Other sites of MR
expression include the retina (Mirshahi et al. 1997), placenta (Hirasawa et al.
2000) and reproductive tissues including the uterus, ovaries and testis (Le Menuet
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et al. 2000).
In comparison to GR, the expression of MR is limited to specific regions of the
central nervous system. The highest levels of MR are found in the limbic system -
particularly in the hippocampus - with lower expression in other limbic structures
such as the lateral septum and amygdale. In addition, MR is also expressed in the
olfactory nucleus, layer II of the cortex and in brainstem sensory and motor
neurons (Arriza et al. 1988; Herman 1993; Reul et al. 2000; Kretz et al. 2001).
Low levels of MR expression are also found in the anterior hypothalamus,
subfornical organ and choroid plexus (Van Eekelen et al. 1988). Within the
hippocampus, MR distribution overlaps with GR in the pyramidal cells of the CA1
and CA2 subregions and in the granule cells of the dentate gyrus (Ito et al. 2000;
Han et al. 2005). In CA3 and CA4 regions, MR expression is considerably higher
than GR in both the adult and the neonatal rats (Avishai-Eliner et al. 2001;
Jongen-Relo et al. 2002).
1.4.2 Glucocorticoid receptor (GR) and mineralocorticoid receptor
(MR) signalling
In the absence of ligand, GR and MR are primarily located in the cytoplasm bound
in a complex with heat shock protein (HSP)-70 and HSP-90 chaperone proteins
(Pratt et al. 2004) and with immunophilins such as FKBP51 (Zhou et al. 2005).
The association of the receptors with HSPs maintains the receptor in a
conformation that permits high-affinity ligand binding (Picard et al. 1990).
Following ligand binding, the receptor undergoes a series of conformational
changes, leading to the detachment of the chaperone proteins which exposes the
nuclear localization signal. These signals recruit a group of nuclear translocation
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Fig 1-4 Schematic illustration of the activation of corticosteroid
receptors. MR and GR dissociate from the chaperone complexes upon
ligand binding and are translocated to the nucleus where they form
homodimers or heterdimers. These dimers bind to Glucocorticoid
response elements (GRE) of the target genes to modulate their
expression. Refer to text for details
53
(Isohashi et al. 1993; Zhou et al. 2005).
Most GR- and MR-mediated gene activation requires dimerization of its receptors
as either homo- or hetero-dimers (ie GR/GR, MR/MR or GR/MR) (Forman et al.
1995; Liu et al. 1995) (Fig 1-4). Formation of heterodimers has been suggested to
provide a more finely orchestrated regulation of corticosteroid-responsive genes
than the actions based on homodimerization alone (Trapp et al. 1994; Trapp et al.
1996). Homodimeric MR/MR and GR/GR or heterodimeric MR/GR bind to a
specific palindromic DNA sequence known as the glucocorticoid response
element (GRE), which is located within the enhancer and/or promoter region of
the target genes (Beato et al. 1995; So et al. 2007). In doing so, this causes
chromatin remodelling and enables the recruitment of components of the basic
transcriptional machinery to allow RNA synthesis (Beato et al. 1995). Figl-4
shows a schematic representation of trans-activation of GR and MR.
Glucocorticoid-response element (GRE: 5'-GGTACAnnnTGTt/cCT-3') has been
well elucidated and shown to be variable extensively around a consensus, but is
strikingly conservative for a given site across species for both GR and MR (Beato
1989; Alnemri et al. 1991; Tsai et al. 1994). However, the existence of an
MR-specific mineralocorticoid-response element (MRE) is still a matter of
controversy. Kolla described a response element designated as (MRE/GRE) in
human Na/K ATPase al promoter which shows greater preference to MR than GR
(Kolla et al. 2000), suggesting the existence of an MRE.
In addition to trans-activation, GR and MR can also repress the transcription of
some specific genes. For example, expression of 5-HTiA receptor gene in
hippocampus is negatively regulated by MR (Nishi et al. 1996; Meijer et al. 1997)
and/or MR/GR heterodimers (Ou et al. 2001). The mechanism of such
trans-repression is similar to trans-activation, which involves the homodimers or
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heterodimers of MR and GR bound to a specific DNA element in the promoter
region of the target gene. This specific DNA element is known as negative GRE
(nGRE). An nGRE shows a highly variable sequence in comparison to GRE
(Truss et al. 1993; de Kloet et al. 2000). Upon binding to nGRE, corticosteroid
receptors can either inhibit the gene expression directly (Aumais et al. 1996) or
occlude adjacent or overlapping binding sites for those positively acting
transcriptional factors, thereby eliciting a negative response indirectly
(Schoneveld et al. 2004). Remarkably, a second mechanism has been described for
GR-mediated trans-repression that binding of the receptor dimers to nGRE is no
longer required. This is achieved by modulating the activity of the other
transcriptional factors or co-activators through protein-protein interactions (de
Kloet et al. 2000; Schoneveld et al. 2004).
1.4.3 Ligand binding
1.4.3.1 Affinity
GR and MR differ in their affinity for corticosteroids. Although GC is the primary
hormone for GR activation, the affinity of GR for GCs (Kj=l-5nM) is
approximately 10 fold lower than MR (Kd=0.3nM) (Reul et al. 1985). However,
GR displays a much higher affinity for synthetic glucocorticoids such as
dexamethasone (DEX) (Reul et al. 1987b) than its endogenous ligand. MR
exhibits a similar high affinity for both aldosterone and GC in a variety of species
including rat, mouse, hamster, dog and human (De Kloet et al. 1975; Veldhuis et
al. 1982; Reul et al. 1985; Rupprecht et al. 1993).
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1.4.3.2 lip-HSDl and llp-HSD2
Although MR binds GC and aldosterone at equal affinity, it selectively bind
aldosterone in the face of up to 1000-fold molar excess of circulating GCs in the
epithelial cells of the kidney, colon, sweat glands which regulate fluid volume and
electrolyte homeostasis (Seckl 1997). This specificity of MR to aldosterone is
dependent on the presence of an enzyme 11 [l-hydroxysteroid dehydrogenase type
2 (11P-HSD2) (Edwards et al. 1988; Funder et al. 1988). At pre-receptor level,
11P-HSD2 converts corticosterone or Cortisol to the inert 11-keto forms so that
they can not bind to MR. Therefore, aldosterone at much lower concentration can
access the receptor and manifest its biological effects (White et al. 1995). This
enzyme is primarily found in the aldosterone target tissues such as distal nephron
of kidney (Moisan et al. 1992), colon (Brown et al. 1996), placenta (Brown et al.
1996) and vascular endothelium (Hadoke et al. 2001). In the brain, it is expressed
in a few and discrete nuclei implicated in mediating central control of salt/water
balance and blood pressure by aldosterone (Roland et al. 1995; Robson et al.
1998).
In addition, there exits another type of enzyme termed as lip-HSDl
(lip-hydroxysteroid dehydrogenase type 1) which has an opposite effect in
comparison to 11P-HSD2. lip-HSDl is capable of regenerating GCs from their
11-keto forms and expressed in a variety of tissues such as liver (Agarwal et al.
1989), lung (Tannin et al. 1991) but absent in aldosterone target cells (Shackleton
et al. 1985; Stewart et al. 1987). In the brain, the expression of lip-HSDl is found
in cerebellum, hippocampus, neocortex, hypothalamus and anterior pituitary
(Seckl et al. 1993; Seckl 1997). The function of lip-HSDl is to potentiate the GC
signals and effects on regulation of HPA axis (Kotelevtsev et al. 1997; Harris et al.
2001), neuronal survival (Rajan et al. 1995) and stress responses (Harris et al.
2001).
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1.4.3.3 U-shape dose dependency of MR and GR in the brain
Crucially the brain contains little 11P-HSD2 and lip-HSDl is expressed in the
hippocampus (Seckl 1997), so MR is predominantly bound to GCs. Because of the
difference in affinity between GR and MR for the ligand, MR is approximately
80%-90% saturated under basal levels of GCs, such as at circadian nadir (Reul et
al. 1987). In contrast, the occupancy of GR is quite low at basal level of
circulating GCs (Reul et al. 1985) and activation of GR requires increased GC
levels in the events such as the circadian peak or a stressful stimulus (Reul et al.
1987a; Reul et al. 1987b). Therefore the cellular responses to GCs in the
hippocampus manifests a U-shape dose-response relationship with plasma
corticosteroids (Diamond et al. 1992; Joels et al. 1994), for example, the
amplitude of depolarisation-induced calcium currents (Joels et al. 2003), the
hyperpolarization cased by serotonin-lA receptor activation (Joels et al. 1991;
Hesen et al. 1996) and glucocorticoid-mediated neuronal vulnerability to toxic
insults (Abraham et al. 2006).
1.4.4 GR and MR in HPA axis
The main function of GR in the brain is to restore the basal activity of the HPA
axis at the hippocampal, hypothalamic and the pituitary levels after stressful
stimuli or during the diurnal peak. Lack of GR function impairs the negative
feedback of GC, in which HPA axis activity is sustained causing chronically high
plasma concentrations of CRH, ACTH and GC (Hesen et al. 1996; Kretz et al.
1999). On the other hand, overexpression of GR in transgenic mice shows lowered
circulating GC levels due to increased sensitivity to the ligand in the
hypothalamus, which suppresses the synthesis of CRH and AVP and subsequently
GC synthesis in the adrenals (Reichardt et al. 2000).
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In the brain MR is occupied to a large extent in the limbic neurons under normal
conditions, which raised the question why constant activation of MR is required. It
was first proposed that MR activation is involved in the tonic inhibitory control of
the hippocampus on HPA activity (De Kloet et al. 1987). This concept was later
tested by various studies using MR antagonist in the animal models. Intra-
-cerebroventricular and intra-hippocampal injection of the synthetic MR
antagonist RU28318 results in an elevation of basal GC levels (Oitzl et al. 1995).
Rats treated with RU28318 or with antisense MR mRNA show increased HPA
response to psychological stressors (Ratka et al. 1989; Reul et al. 1997). Aged
dogs, which generally have enhanced responses to stress, showed decreased septal
and hippocampal MR expression and unaltered GR, accompanied by elevated
basal plasma ACTH and GC levels (Reul et al. 1991; Rothuizen et al. 1993)
Therefore, hippocampal MR enhances inhibitory tone on basal and stress-induced
HPA release in rodents and human (Reul et al. 2000).
1.4.5 Opposing effects of GR and MR in neuronal cell fate
Previous studies suggest that different activation of the dual receptor system,
which is formed by MR and GR, may account for the opposing actions of
corticosterone on neuron proliferation, survival, and death in the brain,
specifically in hippocampal subfield and dentate gyrus (Gould et al. 1996; Hassan
et al. 1996; Reagan et al. 1997).
1.4.5.1 GR in neuronal death
Under stress conditions, increased GR occupation leads to the arrest of
neurogenesis in the dentate gyrus (Gould et al. 1998) and at the same time
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stimulates apoptosis within the granular and hilar cell populations of the dentate
gyrus (Hassan et al. 1996). Experiments using specific GR agonist DEX in
primary hippocampal culture in vitro and in rats in vivo showed that DEX
significantly increased cell death (Crochemore et al. 2005). More importantly, GR
activation has been linked to deteriorating neuronal damage produced by
hypoxia-ischaemia insults (Koide et al. 1986; Packan et al. 1990; Adachi et al.
1998). A surging elevation of GC levels was induced shortly after the ischaemic
insult, which is believed to saturate GR and contributed to the increased cell death
(DeVries et al. 2001; Neigh et al. 2005). Adrenalectomized animals following
ischaemic episode had attenuated neuronal loss in hippocampus (Sapolsky et al.
1985), whereas this protective effect was removed by chronic treatment with DEX
(Koide et al. 1986). Furthermore, the administration of selective GR antagonist
RU38486 in adult rats significantly protected hippocampal CA1 pyramidal cells
from transient cerebral ischaemia (Antonawich et al. 1999). The mechanisms of
this GR-induced neuronal endangerment are not entirely clear, but implied to be
associated with energy-dependent elevation of extracellular glutamate
9+
concentrations and subsequently the increased intracellular Ca influx (Sapolsky
1986; Virgin et al. 1991; Elliott et al. 1993; Adachi et al. 1998). It has also been
suggested by Almeida that cell death due to GR activation was attributable to the
up-regulation of the pro-apoptotic gene, Bax, and its direct transcriptional
regulator, p53 (Almeida et al. 2000).
1.4.5.2 MR in neuroprotection
MR signalling is essential for cell survival. Animals adrenalectomized for a period
of 3-7 days show a substantial decrease in cell number in hippocampal dentate
gyrus (Gould et al. 1990). However, replacement with aldosterone in those
animals protected the cells from death but DEX had no effects, confirming MR
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not GR activation is required for neuronal survival (Woolley et al. 1991; Sloviter
et al. 1995). Further evidence came from MR knockout mice, which showed
impaired neurogenesis and degeneration of the hippocampal granule cells in
adulthood (Gass et al. 2000). In primary hippocampal culture, DEX-induced cell
death was rescued by treatment with aldosterone and this protective effect was
abolished by the MR antagonist (Crochemore et al. 2005). Taken these together, it
suggests MR activation at physiological concentrations of GCs plays a vital role in
maintaining the neuronal viability and hippocampal integrity and counteracting
GR-induced cell death.
Our group has shown that MR mRNA and protein are rapidly increased in rat
primary cortical and hippocampal cultures in response to the general-apoptosis
inducer staurosporine. This increase in MR was associated with enhanced survival
since MR antagonism with spironolactone removed this protective effect
(Macleod et al. 2003). MR induction was also observed in vivo in rat hippocampus
after exposure to hypothermic transient global ischaemia. Similarly, the
administration of spironolactone promoted cell death (Macleod et al. 2003).
Importantly, overexpression of MR in PC12 cells protected against cell death
caused by staurosporine and by oxygen-glucose deprivation (in vitro ischaemic
insult). This survival effect was again abrogated by MR antagonism (Lai et al.
2005) and similarly in vivo, transgenic mice overexpressing MR specifically in the
forebrain displayed protected against the damaging effects of transient global
cerebral ischaemia (Lai et al. 2007).
Increased MR expression was only found in the hypothermic ischaemic group but
not in hypothermic or ischaemic groups alone, indicating that MR may be
involved in endogenous survival pathways triggered by hypothermia and cerebral
ischaemia. Although the mechanisms of MR in neuroprotection are not entirely
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clear, evidence suggests MR activation leads to overall decreased NMDA receptor
activity followed by reduced calcium influx (Nair et al. 1998). In addition, MR
signalling promotes the expression of the anti-apoptotic protein Bcl-2 and Bcl-xl
(Almeida et al. 2000; McCullers et al. 2001) as well as basic fibroblast growth
factor and neurotrophic factors such as brain-derived neurotrophic factor (BDNF)
and neurotrophin-3 (NT3) (Hansson et al. 2000).
Interestingly MR mRNA levels have recently been found to be increased in the
hippocampal neurons in human post-mortem brains from patients who suffered
from transient global ischaemia due to cardiac arrest several days before their
death (Lai M, Macleod M, in press), implying that a similar injury-induced MR
neuroprotective mechanism exists in the human brain. Therefore manipulation of
MR may provide a novel treatment strategy for conditions involving cerebral
ischaemia.
1.4.6 Challenges to developing MR-based neuroprotective agents
Given the body of evidence indicating the beneficial effects of MR on neuronal
survival, manipulation of MR signalling therefore appears to be a possible strategy
for treating conditions involving cerebral ischaemia. Importantly, up-regulation of
MR must be specific to neurons and not other types of cells. Since MR is almost
saturated at basal level of circulating GCs, increasing MR signalling will require
increased abundance of receptor instead of ligand concentration.
1.4.6.1 MR expression in glial cells
Except for neurons, MR is also expressed in glial cells such as astrocytes and
oligodendrocytes (Chou et al. 1991; Cintra et al. 1994). Since glia cells provide
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nutritional support, regulate the chemical environment, maintain the structural
integrity and an immune defence system to the neurons in the CNS (Ransom et al.
2003; Volterra et al. 2005; Haydon et al. 2006), if MR signalling can protect glial
cells from ischemic insult, it is reasonable to predict the MR up-regulation in glial
cells will also be beneficial for neuronal survival in an indirect manner. However,
few direct studies on the function of MR activation in glial cells in response to
cerebral ischemia are available except one, which was reported by Hwang, who
measured MR expression in astrocytes in response to transient global ischemia in
gerbil and demonstrated an increased expression of the MR but failed to measure
neuronal or glial viability (Hwang et al. 2006). Indirect evidence showed
hypoxia-induced cell death was enhanced by additional GCs treatment in astrocyte
culture in vitro whereas this deleterious effect is believed to be associated with GR
activation instead of MR solely (Tombaugh et al. 1993). Therefore the function of
MR activation in glial cells is still a mystery. In terms of drug development, it is
more realistic and promising to focus on the augment of MR signalling in neurons,
which is confirmed to exert protective function directly.
1.4.6.2 MR expression in vascular system
Activation of MR in cerebral vessels causes vascular remodelling and eventually
lead to hypertension which itself is a risk factor for ischaemic stroke. The first
report by Conn et al. in the 1960s proposed a link between hypertension, stroke
and elevated plasma aldosterone levels (Conn et al. 1964). This link was further
consolidated by studies using inhibitors of the rennin-angiotensin- aldosterone
system (RAAS), which conferred greater protection from stroke than a reduction
in blood pressure alone (Hilleman et al. 2004; Sokol et al. 2004). This suggests
that reduced aldosterone concentration and presumably reduced MR activation is
at least part of the beneficial effects. Experiments in stroke-prone spontaneously
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hypertensive rats revealed that MR activation in cerebral vessels resulted in a
reduced lumen size without a significant change in wall thickness (Dorrance et al.
2006). Furthermore, administration of MR antagonist spironolactone in these
animals significantly reduced damage caused by cerebral ischaemia by 50%
(Dorrance et al. 2001).
Therefore, these findings in which increased MR signalling in different tissue and
cell types can either be beneficial or detrimental to cerebral ischaemic outcome
suggest that developing MR based treatments needs to be specifically targeted. In
order to do this a thorough understanding of the transcriptional regulation ofMR
is crucial.
1.4.7 The transcriptional regulation of MR
It is now clear that the MR gene does not transcribe just for one unique mRNA,
but rather for a number of variants, in a manner analogous to GR (Yudt et al.
2002). The mechanism involved in generating distinct MR variants is known as
alternative splicing, which is believed to potentiate the diversity of protein or
mRNA species from a single gene.
The rat MR gene gives rise to three distinct MR mRNA transcripts (MRa, p,
y) which differ in their 5'-untranslated regions but encode the same mature protein
(Kwak et al. 1993). Each corresponding 5'-flanking region acts as a functional
promoter allowing independent regulation of each mRNA variant. Similarly, the
human MR gene generates two MR mRNA species controlled by two separate
promoters (PI and P2) which correspond to rat MRa and MRP respectively
(Zennaro et al. 1995; Zennaro et al. 1996). Both RNase protection assay and in
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Fig 1-5 Schematic representation of MR gene in rat (A) and human (B) and
mRNA variants in rat (C) and human (D). The rMR is composed of 11 exons,
including three untranslated first exons (la, 1(3 and ly) while the other exons
encode the entire protein. The ATG translational start codon is located at 2bp of
exon2, while the stop codon is located in exon9. Under the control of its own
promoter, transcription of these 5'-untranslated exons generates three different
mRNA variants, termed rMRa, rMRp and rMRy in rat. Human MR has two
mRNA variants, termed hMRa and hMRp, and transcription is directed by
promoters PI and P2 separately. TAA=stop codon.
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in adult rat hippocampus, occupying 60% of total MR while MRy is much less
abundant (~ 3%). The ratio of transcripts however differ in different tissues, for
example in the kidney the MRa variant is the only predominant variant and both
rMR(3 and rMRy are poorly expressed (Kwak et al. 1993). The pattern of
transcripts also depends on the stages of development: in the hippocampus of
neonatal rat, rMRy is highly expressed from postnatal day 3 to day 7 then declines
rapidly; whereas, rMRa mRNA levels remain throughout development (Vazquez
et al. 1998).
Little is known about how each variant MR transcript is regulated. To investigate
this a 1500bp promoter fragment of the MRa variant was generated by Castren
(Castren et al. 1993) and promoter activity was found to be up-regulated by
corticosterone and progesterone (Castren et al. 1995; Castren et al. 1995a). Other
regulators of MRa have yet to be identified and to date there are no reports on
how rMRp or rMRy are regulated.
1.4.8 The translation ofMR
Given the translation initiation site is located 2bp downstream from the beginning
of exon2, all of MR mRNA variants encode the same protein product (Pascual-Le
Tallec et al. 2005). However, there exist some MR protein variants as well, for
example, a 12bp insertion at the exon3/intron splice junction leads to an inframe
insertion of four amino acids in the DNA binding domain (Bloem et al. 1995) and
this variant has no different in transcriptional activity in comparison to wild type
MR (Bahr et al. 2004). Another protein variant is the lObp deletion in the rat MR
in the ligand binding domain, which is expressed at a low level and manifests
unresponsiveness to aldosterone (Zhou et al. 2000). The reason for the MR protein




Previous work suggests that MR is important in promoting neuronal survival for
example in response to the damaging effects of cerebral ischaemia. How MR is
regulated under such conditions has yet to be elucidated. Therefore identifying the
exact mechanism should inform and guide the development of novel and effective
MR-based treatment strategies for conditions causing cerebral ischaemia and other
neurodegenerative diseases.
The overall aim of this thesis was to investigate in detail the transcriptional
regulation of the rat MR gene in response to different cellular stressors. To
accomplish this goal, investigations were carried out in three different models—in
cell lines, primary neuronal cortical culture and in an in vivo model. Specifically,
the aims were:
(i) To elucidate the transcriptional regulation of MR in vitro at the
promoter level in response to different types of cell stress.
(ii) To demonstrate that altered promoter activity in response to cell stress
corresponds to changes at the transcript level in vitro.






2.1.1 Agarose gel electrophoresis
0.8% agarose gels were typically prepared for analyzing DNA fragments and
plasmids by electrophoresis. Agarose was dissolved in lx Tris/acetic acid/EDTA
(TAE) buffer by boiling in a microwave oven. Ethidium bromide (final
concentration 0.2ug/ml) was added to the molten agarose and cast in horizontal
gel trays. Set gels were submerged in lx TAE in standard gel electrophoresis tanks,
then samples suspended in lx DNA loading buffer (Orange G) were loaded into
the wells. DNA was separated by electrophoresis under constant voltage
conditions between 100-120V. Sizes of DNA fragments were estimated by
comparison with fragments derived from lkb or lOObp DNA ladders run in
parallel. Resolved DNA fragments were visualized by placing agarose gel on a
UV transilluminator at a wavelength of 254nm.
2.1.2 Denaturing polyacrylamide/urea gel electrophoresis
Samples from ribonuclease protection assays (RPA) were resolved through
denaturing polyacrylamide gels. Prior to use, glass plates were carefully washed
with detergent, rinsed with water and cleaned with 100% ethanol and left allowed
to air dry. Plates were assembled according to the manufacturer's instructions
using 0.8mm spacers. 6% Polyacrylamide/7M urea gels were made up by
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dissolving 10.5g of urea in 3.75ml 40% acrylamide:bis-acrylamide (19:1), 2.5ml
lOx TBE buffer made up to 25ml with nuclease-free water. 150ul ammonium
persulphate (10%) and 25ul TEMED were added to the gel solution to accelerate
polymerization and the gel solution was poured immediately. Wells were flushed
well prior to sample loading which were run separated at constant voltage 250V
for 3 hours.
Following electrophoresis gels were laid onto 3M Whatman paper and
vacuum-dried on a BioRad Model 583 Gel drier at 80°C for 1 hour. Dried gels
were exposed to BioMax MS autoradiographic film for 3-7 days at -80°C or to
phosphorimager screens at room temperature for 3-7 days. Exon 1 specific MR
fragments were quantified using a Fujifilm FLA-2000 phosphorimager and Aida
v2.0 software.
2.2 PCR-based techniques
2.2.1 Polymerase Chain Reaction
PCR was carried out to generate DNA fragments containing promoter regions of
MRP and MRy variants from rat genomic DNA. For each reaction, O.lug of rat
genomic DNA was mixed with forward and reverse primers (final concentration
0.3uM each), 2.5 units of accuprime Pfx polymerase, lx acumprime Pfx buffer
containing ImM MgCl2 and dNTP (0.3mM each), made up to a volume of 50ul
with amplification-grade water. A negative control containing water instead of
DNA template was also carried out in parallel. All PCR reactions were performed
in a thermal cycler using 0.2ml thin-walled eppendorf tubes. The conditions for
PCR reactions are described in detail in Tab 2-1. PCR products were kept at 4°C
and analyzed by electrophoresis on 0.8% agarose gels to determine the size of
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amplification products.
2.2.2 Reverse transcriptase polymerase chain reaction
The DNA templates for synthesizing specific cRNA riboprobes for RPA (Chapter
4) and in situ hybridization (Chapter 5) were generated by reverse transcription-
PCR (RT-PCR).
First strand cDNA was synthesized by reverse transcription from total RNA of rat
hippocampus (for RPA) or cortical culture (for in situ hybridization). RNA (2ug)
was denatured at 72°C for 10 minutes then added to the reverse transcription
reaction which contained 5mM MgCl2, lx reverse transcription buffer, ImM dNTP,
40 units RNase inhibitor, random primer (0.5ug) and 15 units AMV reverse
transcriptase in a total volume of 20ul. The reaction mixture was incubated at
room temperature for 10 minutes and then heated to 42°C for 2 hours to allow
efficient reverse transcription from the primers and then to 95 °C for 5 minutes to
inactivate reverse transcriptase.
Synthesized cDNA (2ul) was then used for PCR amplification in a reaction mix
containing lx Taq polymerase buffer, 1.5mM Mg2+, 0.2mM dNTP, forward and
reverse primers (0.2uM of each primer) and 1.25 units Taq DNA polymerase. The
PCR conditions are stated in Tab 2-2 and Tab 2-3. Amplified PCR products were
analyzed by electrophoresis through 0.8% agarose gels.
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Table 2-1 PCR conditions for generation ofMRP and MRy promoter fragments
Sample
Size
Denaturation Cycles Thermal cycle conditions Extension
pMRJ3 300bp 95°C 2min 30 95°C, 15s; 59°C, 30s; 68°C, 2min 68°C, lOmin
pMRy 1.7kb 95°C 2min 30 95°C, 15s; 59°C, 30s; 68°C, 2min 68°C, lOmin




Denaturation Cycles Thermal cycle conditions Extension
MRa 390bp 94°C 5min 35 94°C, 40s; 54°C, 40s; 72°C, 2min 72°C, lOmin
MRP 206bp 94°C 5min 35 94°C, 40s; 54°C, 40s; 72°C, 2min 72°C, lOmin
MRy 300bp 94°C 5min 35 94°C, 40s; 54°C, 40s; 72°C, 2min 72°C, lOmin
Table 2-3. PCR conditions for generation ofMR specific exon 1 DNA fragments
(In situ hybridization)
Sample Denaturation Cycles Thermal cycle conditions Extension
Size
MRa 200bp 94°C 5min 35 94°C, lmin; 52°C, 30s; 72°C,
lmin
72°C, lOmin
MRP 383bp 94°C 5min 35 94°C, lmin; 52°C, 30s; 72°C,
lmin
72°C, lOmin














































Table 2-7 Materials for PCR based techniques and electrophoresis
PCR and RT-PCR
Reverse transcription system Promega
TaqBead polymerase kit Promega
Pfx polymerase kit Invitrogen
lOOmM dNTPs Promega
Nuclease-free water Promega





lkb DNA ladder Invitrogen
lOOkb DNA ladder Invitrogen
Low mass DNA ladder Invitrogen
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2.3 Cloning of DNA
2.3.1 Blunt-ending of PCR products
PCR products for promoter constructs were blunt-ended by treatment with Klenow
polymerase (5 units) in lx DNA polymerase buffer, dNTP (lOOuM each), 0.5ul
BSA in 20ul mixture for 10 minutes at room temperature. Reactions were
terminated by incubation at 75°C for lOminutes.
2.3.2 Preparation of plasmid vector for cloning
The pGL3 vector was prepared for ligation with promoter fragments firstly by
linearization with Smal. For this, 2ug of empty vector was mixed with lx
restriction digest buffer, 10 units of restriction enzyme Smal, made up to a volume
of 20ul with distilled H20 and incubated at room temperature for 2 hours. Gel
electrophoresis was performed to confirm successful digestion. Linearized vector
then underwent 5' dephosphorylation using calf intestinal alkaline phosphatase (10
units, CIAP) in lx CIAP buffer for 30 minutes at 37°C. To terminate the reaction,
GAP was inactivated by addition of 2ul 0.5M EDTA (pH8.0) and incubation at
65 °C for 20 minutes.
Riboprobe template construct was generated by TA cloning using pGEM T-Easy
vector which was pre-linearized with EcoRV.
2.3.3 DNA purification
Vector DNA and PCR fragments were subjected to either gel purification or
74
normal purification. 30ul PCR products and linearized vectors were resolved
through 1% gel made with low-melting point agarose stained with ethidium
bromide (final concentration 0.2ug/ml). DNA was visualized using a UV
transilluminator at a wavelength of 365nm and the required fragment was excised.
DNA was released from the agarose using the Roche DNA purification kit
according to the manufacturer's instructions. Briefly, excised pieces of gel
containing DNA were dissolved in extraction reagent and incubated at 55°C for 10
minutes. DNA was isolated and purified by addition of isopropanol then passage
through a filter spin column at 13,000rpm for 1 minute. Filter columns were
washed twice with buffer containing 70% ethonal to remove residual salts before
the DNA was eluted with 20ul elution buffer. The concentrations of recovered
PCR products and vector plasmid were estimated by comparison with DNA bands
from a low-mass DNA ladder on agarose gels.
2.3.4 Ligation of vector and PCR products
PCR inserts were ligated into plasmid vectors was using a ratio of 1:3 of vector
and insert in a reaction containing lx T4 DNA ligase buffer and 3 units of T4
ligase, made up to a total volume of 20ul with milli-Q water. Ligation reactions
were carried out at 12°C for a minimum of 16 hours.
2.3.5 Transformation of DNA into bacteria
Ligation products were transformed into DH5a maximum efficiency competent
cells. Cells were thawed on wet ice and 200ul aliquots transferred into chilled
tubes. l-1.5ul ligation mixture was added to the competent cells with gently
swirling, followed by incubation on ice for 30 minute. Cells were then subjected
to heat shock at 42°C for exactly 45 seconds and returned immediately onto ice
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for a further 2 minutes. 1ml of SOC medium was added to the cells and incubated
in an orbital shaking incubator at 180rpm at 37°C for 1 hour. Cells were spun at
3000 rpm for 30 seconds to allow sedimentation, 800ul medium was removed and
cells were resuspended in the remaining 200ul SOC medium. The transformation
mixture was plated out onto LB agar plates containing lOOug/ml ampicillin. Plates
were allowed to air dry for 5-10 minutes, inverted and incubated at 37°C
overnight.
2.3.6 Mini-preparation (small-scale preparation of plasmids DNA)
Positive recombinants were screened by small-scale preparation of plasmid DNA
followed by restriction digestion. For each plate, 20 individual positive colonies
and cultured in 2 ml LB culture medium containing lOOug/ml ampicillin in an
orbital shaking incubator at 180rpm at 37°C overnight. Grown cultures were
transferred into microcentrifuge tubes, and cells were sedimented by
centrifugation at 6,000rpm for 3 minutes. Cell pellets were resuspended in lOOul
ice-cold GTE buffer and incubated at room temperature for 5 minutes. Cells were
then mixed with 200ul freshly-prepared 0.2M NaOH and 1% SDS and incubated
on ice for 5 minutes before the addition of 150ul 5M potassium acetate (pH4.8)
and incubation on ice for a further 5 minutes. Lysed cells were centrifuged at
13,000rpm at 4°C for 5minutes and the resulting supernatant containing plasmid
DNA was collected and extracted with an equal volume of
phenol/chloroform/isoamyl alcohol (25:24:1) followed by extraction with
chloroform/isoamyl alcohol (24:1). DNA was precipitated with 2 volumes 100%
ethanol, collected by centrifugation, washed with 70% ethanol and air-dried. Each
DNA sample was dissolved in 20ul nuclease-free water. Residual RNA was
removed by treatment with 20ur.->s of RNase A at 37°C for 20 minutes. The
concentration of plasmid DNA was measured by UV spectrophotometry.
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2.3.7 Large-scale (maxi) preparation of plasmid DNA
Positive recombinants containing insert in the correct orientation as determined
from the initial screening process were cultured for large scale plasmid DNA
preparation. Initially, a sample from that colony was seeded in 2ml LB medium
containing lOOug/ml ampicillin at 37°C for 6 hours. The culture was then
transferred to 500ml ampicillin-containing LB medium and incubated in an orbital
shaking incubator at 37°C for a further 16 hours.
Cells were sedimented by centrifugation in pre-chilled tubes at 6,000 rpm for 5
minutes at 4°C in a Beckman J2-MC centrifuge. Cell pellets were resuspended in
12ml ice-cold GTE and mixed with 24ml freshly prepared 0.2M NaOH and 1%
SDS and allowed to incubate on ice for 10 minutes. Cells were then mixed with
16ml ice-cold 5M potassium acetate placed on ice for a further 10 minutes. Cell
lysates were centrifuged at 6,000rpm for 10 minutes at 4°C and collected
supernatant was passed through gauze filters to remove residual cell debris.
Plasmid DNAwas retrieved by precipitation with 32ml isopropanol for 30 minutes
at room temperature, and centrifugation at 10K rpm for 3 minutes. Air -dried
DNA pellets were redissolved in 2.2ml TE buffer and subjected to caesium
chloride (CsCl2, lg/ml) gradient ultracentrifugation at 70K rpm for 20 hours in the
presence of 0.4mg/ml ethidium bromide. Plasmid DNA contained within the
ethidium bromide layer was collected and subjected to further ultracentrifugation
at 100,000rpm for 4 hour, re-collected then extracted from the ethidium bromide
with chloroform. Finally, plasmid DNA was purified by dialysis in TE buffer for a
minimum of 18 hour with at least 3 changes of dialysis buffer.
The concentration of plasmid DNAwas measured by UV spectrophotometry.
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2.3.8 DNA sequencing
Plasmid DNA containing the inserts of interested were verified by DNA
sequencing using appropriate sequencing primers via a commercial company (The
Sequencing Service, University of Dundee)..
2.3.9 DNA concentration
Plasmid DNA concentrations were assessed by measurement of optical density
using a GeneQuant RNA/DNA spectrophotometer. Diluted DNA (total lOOul) was
transferred into quartz cuvettes and absorbance values measured at a wavelength
260nm. To determine the purity of the DNA, absorbance values were also
measured at 280nm and the ratio of absorbance at 260/280nm calculated. Values
between 1.7 and 1.9 indicated purity of 80% to 100%. Each sample was measured
in duplicate and mean values taken to be the concentration of that sample.
2.3.10 Restriction digests
To determine the orientation of insert DNA in the plasmid, restriction mapping
was performed. Each reaction was comprised of lug plasmid DNA, 2ul lOx
appropriate digestion buffer, 0.2ug BSA and 10 units of restriction enzyme(s), in a
total volume of 20ul. Restriction digests were incubated at 37°C for 1-2 hours,
then fragments were visualized by gel electrophoresis. The enzyme(s) used for
promoter construct pMRjl 300 were Kpnl and SacII, for pMRy was Xhol. The
enzyme for all riboprobe plasmid template constructs was Notl.
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2.3.11 Materials
Table 2-8 Materials for DNA cloning
pGL-3 basic Promega
pGEM-T-easy vector system Promega
DH5a competent cells Invitrogen
Ampicillin Sigma-Aldrich
LB agar Sigma-Aldrich





All restriction enzymes Promega
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2.4 Cell culture
2.4.1 Poly-D-lysine preparation and plate coating
Poly-D-lysine was dissolved in autoclaved tissue culture grade H2O to give a final
concentration of 50ug/ml and a sufficient volume was used to coat 6-well plates
for 1-6 hours at 37°C. Once coated, poly-D-lysine was aspirated from the wells
and plates were left to dry in a standard tissue culture incubator overnight. Dried
poly-D-lysine coated plates were stored then at 4°C. Prior to use, wells were
briefly rinsed with lx PBS.
2.4.2 Preparation of rat primary cortical cultures
Rat primary cortical cultures were prepared from the foetuses of El 8 ± 0.5 day old
Wistar rats. Dams were sacrificed by cervical dislocation and foetuses were
quickly removed from the uterus. Cerebral cortices were dissected from each
foetal brain and the meninges were carefully removed and discarded. Cortices
were finely chopped then digested in Hanks balanced Salt solution (HBSS)
containing trypsin (1800U/ml) and DNase I (500U/ml) for 10 minutes at 37°C
with occasionally agitation. Trypsinization was stopped by addition of trypsin
inhibitor solution (0.45mg/ml) and digested cells were collected by centrifugation
at lOOOrpm for 5 minutes at room temperature. Cells were resuspended in 10ml
DNase I solution (500u/ml) and dissociated by trituration through a 21-gauge
needle. Cells were centrifuged at lOOOrpm for 10 minutes, resuspended in
Neurobasal A culture medium containing B-27 supplement, 1% L-glutamine
(0.5mM) and 1% penicillin/streptomycin (50U/ml) and plated at a density of
2xl06/well (6 well plates for culture), 8xl05/well (12-well plates for
immunohistochemistry) or 1.5xl05/well (48-well plates for time-response curve).
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Cultures were incubated under standard tissue culture conditions at 37°C for 14
days with culture medium replaced on day 7.
2.4.3 Preparation of collagen
Collagen type IV was dissolved in 0.1M glacial acetic acid solution, mixed at
room temperature for 2 hours and then sterilized by incubation with 10ml of
chloroform which was carefully added to form a layer beneath the collagen. After
overnight incubation at 4°C, the aqueous upper layer containing the collagen was
aseptically removed and stored in a sterile vial at 4°C until ready for use.
2.4.4 Treatment of cultureware with collagen
Sufficient collagen was added to cover the surface of 75cm3 standard tissue
culture flasks or the bottom of multiwell plates and incubated overnight in a
standard tissue culture incubator. The collagen was then removed and coated
flasks and plates were left to dry at 37°C in tissue culture incubators. Prior to use,
the flasks/plates were rinsed twice with lx PBS.
2.4.5 Maintenance of PC12 cell line
Rat pheochromocytoma PC12 cells were maintained as monolayers in 10ml
complete medium comprised of Delbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 5% horse serum (HS), 1%
L-glutamate(2mM) and 1% penicillin/streptomycin (50U/ml) in collagen-coated
flasks (prepared as described above). Cells were routinely incubated in standard
tissue culture incubators at 37°C under humidified conditions of 95% atmospheric
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air/5% CO2. Confluent cells were split every 4-5 days: monolayers were initially
rinsed with 2ml trypsin/EDTA then detached from flasks by incubation at 37°C
with 5ml trypsin/EDTA. To split cells, 4.5ml of the cell suspension was removed
and the remainder was diluted with complete medium and grown as described.
2.4.6 Cell harvest
PC12 cells were seeded into collagen coated 6-well plates for experimental set-ups
as follows: monolayers were detached from flasks as described above and
transferred to falcon tubes containing 10ml complete medium. Cells were
collected by centrifugation at lOOOrpm at room temperature for 5 minutes. The
supernatant was carefully aspirated and the cell pellet was resuspended in 10ml
complete medium.
The number of harvested cells was counted with the aid of an improved Neubauer
haemocytometer. The original cell suspension was then made up to the given
concentration of cells with the required volume of complete medium. For
experiments involving undifferentiated cells, cells were seeded at a density of
lxl04/cm2 and for experiments involving differentiated cells, cells were seeded at
a density of 6xl03/cm2.
2.4.7 Preparation of NGF
PC12 cells were differentiated using nerve growth factor (NGF). Lyophilised NGF
was prepared by dissolution in glucose-free DMEM culture medium to give a
stock concentration of O.lmg/ml and stored in lOul aliquots at -80°C until ready
for use.
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2.4.8 Establishment of differentiated PC12 cells
Undifferentiated PC12 cells in complete medium were seeded into 6 or 12 well
culture plates and left to grow for 24 hours. Culture medium was aspirated and
replaced with serum-free DMEM medium containing 2mM L-glutamine and
50U/ml penicillin/streptomycin and returned to the tissue culture incubator for at
least 1 hour. NGF was added to each well at a concentration of lOOng/ml and
allowed to grow for a further 3 days before experimentation.
To ensure PC12 cells exposed to NGF were terminally differentiated, 3 different
assessments were made:
i) Cell morphology
Cell morphology was observed at various timepoints using an optical light
microscope and images were recorded using an MCID M4 image analysis system.
ii) Cell proliferation
Cell proliferation was determined using the MTS proliferation system. MTS assay
buffer was brought to a temperature of 37°C and added to each well to give a
dilution of 1:5. For negative controls, wells containing serum-free DMEM
medium in the absence of cells were used. Cells were returned to tissue culture
incubators for 2 hours then 50ul culture medium was removed from each well and
the amount of formazan product present in the medium was measured in a 96-well
plate reader at a wavelength of 490nm. Samples from each well were measured in
duplicate.
iii) Expression of tyrosine hydroxylase
PC12 cells previously exposed to NGF for 3 days were subjected to
immunocytochemistry to detect tyrosine hydroxylase and compared with
undifferentiated PC12 cells. Briefly, after removal of culture medium, cells were
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washed twice with lx PBS then fixed with 4% ice-cold paraformaldehyde for 30
minutes at 4°C. Fixed cells were washed repeatedly with lx PBS, incubated with
0.6% hydrogen peroxide for 15 minutes to quench endogenous peroxidase, then
permeabilized with 0.3% Triton X100 in lx PBS for 3 minutes. To prevent
non-specific binding cells were incubated with 1.5% horse serum for 1 hour at
room temperature before overnight incubation at 4°C with an anti-tyrosine
hydroxylase monoclonal antibody (1:500 dilution). Cells were washed three times
with lx PBS and incubated with a biotinylated anti-mouse secondary antibody
(1:5000 dilution) for 1 hour at room temperature. Bound antibody was detected
using the Vectastain Elite ABC kit according to the manufacturer's instructions
and visualized colorimetrically with diaminobenzidine (DAB) Differentiated cells
without primary antibody incubation served as the negative control. Immuno-fixed
cells were examined under a light microscope and images taken using MCID
image analysis system.
Immunocytochemical analysis of primary cortical culture
To determine the percentage population of neurons versus glia in rat primary
cortical cultures, immunocytochemistry was used to detect the neuronal marker
microtubule-associated protein 2 (MAP2) and the glial marker, glial fibrially
acidic protein (GFAP). Cells were fixed, incubated in a rabbit polyclonal
anti-GFAP (1:500) or a monoclonal anti-MAP2 (1:200) and processed for
detection as described above with the appropriate biotinylated secondary antibody.
Immunostaining was observed by light microscopy and the proportion of neuron
to glial cells was calculated by counting the number of stained neurons and glia
from 10 randomly selected fields per well.
2.4.9 Cell stressors
Undifferentiated and differentiated PC12 cells were exposed to six different types
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of cellular stressors: staurosporine, NMDA, H2O2, hypothermia, OGD and
combined OGD and hypothermia (OGD&hypothermia) for given periods of time.
Staurosporine was dissolved in anhydrous dimethylsulphoxide (DMSO) to a stock
concentration of lOmM, and stored in 5ul aliquots at -80°C. Aliquots were thawed
and subjected to serial dilution in serum-free DMEM culture medium before being
added to cells to give final concentrations ranging from O.lnM to lOuM.
NMDA was dissolved in DMEM to give a stock concentration of 1M and pH
adjustments were made were necessary. Serial dilutions were made from
neutralized stock NMDA and added to the cells to give final concentrations
ranging from lOuM to lOmM.
Cells were subjected to hypothermia by incubation at 33°C in a standard tissue
culture incubator. Normal culture medium was aspirated and replaced with
medium pre-warmed to 33°C. Cells were incubated at the 33°C for a given time
then returned to 37°C for a total duration of 24 hours.
Oxygen-glucose deprivation (OGD) was performed in a custom made
temperature- and C02-controlled chamber containing 1%02/5%C02/94%N2
(200bar). Cells were introduced into the glove box where the normal culture
medium was aspirated and replaced with glucose-free DMEM culture medium
previously pre-equilibrated in the glove box for at least 30 minutes. Cells were
incubated in the hypoxic chamber for a given time and returned to standard culture
conditions with the addition of 0.45% glucose (wt/vol).




The amount of lactate dehydrogenase (LDH) released by cells was measured to
determine the extent of cell damage following exposure to cell stress using a
commercially available kit. Briefly, 50ul culture medium from each well was
transferred to a 96-well plate, mixed with 50ul LDH assay buffer and incubated at
room temperature for 30 minutes in the dark. The reaction was stopped by
addition of acetic acid (1M) and absorbance was measured at 490nm. To measure
total LDH, cells were lysed with 1% Triton X100 at 37°Cfor 45 minutes then 50ul
cell lysate was analysed for LDH as described above.
To calculate the amount of LDH released by cells in response to cell stress, the
percentage of cell damage was calculated using the equation described in
Appendix 2.
2.4.11 Transient transfection
Undifferentiated PC12 cells were seeded at the required density in collagen coated
multiwell plates and incubated under standard culture conditions. Cells were
transiently transfected with relevant reporter plasmids when they had reached
50-60% confluency. Initially, culture medium was aspirated from cells and
replaced with antibiotic-free complete DMEM medium at least 1 hour prior to
transfection.
For transfection studies in undifferentiated PC12 cells, 0.5ug promoter
insert-containing plasmid DNA per well was mixed with 0.5ug of the
(Lgalactosidase encoding pCHllO plasmid (internal control) in 50ul Optimem™
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medium. The DNA mixture was transfected into cells using lipofectamine 2000™
(lul/ug DNA) according to the manufacturer's instructions. Cells transfected with
0.5ug promoterless pGL3-basic vector served as the baseline control. Transfected
cells were subjected to cell stress 24 hours later.
For promoter studies involving differentiated PC 12 cells, initially 0.375ug insert
containing plasmid and 0.375ug pCHllO plasmid were transfected into 50-60%
confluent undifferentiated cells as described above. Transfected cells were
differentiated 24 hours later: culture medium was replaced with serum-free
antibiotic containing DMEM medium then cells were treated with NGF (lOOng/ml)
and maintained under standard incubation conditions for a further 3 days before
exposure to cell stress (as described in 2.4.9).
2.4.12 Luciferase and P-galactosidase assays
24 hours after the start of cell stress, cells were harvested for measurement of
luciferase and P-galactosidase (P-gal) activity. Cells were washed with lx PBS
and lysed in luciferase lysis buffer. Cell lysates were collected and centrifuged at
13,000rpm for 2 minutes at room temperature to remove debris. To measure
luciferase activity, 40ul of cell lysate from each sample was mixed with lOOul 2x
luciferase assay buffer and 5ul lOOmM ATP, and placed into a single-tube
luminometer then lOOul ImM beetle luciferin was injected to the lysate mixture.
Luciferase activity for each sample was performed in triplicate. The amount of
chemiluminescence emitted was directed related to luciferase activity as described
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Fig 2-1. Bioluminescent reaction catalyzed by firefly luciferase. (Promega)
(A) and P-galactosidase (B)
P-gal activity was measured according to the method developed by Jain and
Magrath (Jain et al. 1991), using the Tropix/Galacto Light kit. For each sample
(performed in triplicate), 1 Oul cell lysate was mixed with 67ul Galacto-Light assay
buffer and incubated at room temperature for a minimum of 20 minutes at room
temperature. P-gal activity was measured in a single-tube luminometer following
addition of lOOul chemiluminescent accelerator solution. Luciferase activity was
then expressed relative to p-gal activity.
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2.4.13 Materials
Table 2-9 Materials for cell culture, stressors, transfection and reporter assay
General cell culture
6-well cell culture plate
12-well cell culture plate
48-well cell culture plate
96-well cell culture plate Corning
60mm culture dishes
'■s
75mm cell culture flasks
5 ml sterile pipettes
10 ml sterile pipettes
25 ml sterile pipettes
Plate/dish coating
Poly-D-lysine Sigma-Aldrich
Collagen (type IV) Sigma-Aldrich
PC 12 cell culture
DMEM medium Lonza
DMEM medium (glucose-free) Invitrogen
HBSS Lonza




trypsin/EDTA (0.25% trypsin; ImM EDTA) Lonza
NGF Upstate







Establishment of differentiated PC 12 cells
MTS assay kit Promega
LDH assay kit Promega
Mouse anti-TH monoclonal antibody Chemicon
Mouse anti-MAP2 monoclonal antibody Sigma-Aldrich
Rabbit anti-GFAP polyclonal antibody Sigma-Aldrich







Transfection and reporter gene assay
Optimem medium Invitrogen
Lipofectamine 2000 transfection reagent Invitrogen
Firefly Bettle Luciferin Promega





All RNA work was performed with utmost care to avoid RNA degradation by
ribonucleases. All materials were autoclaved and equipment was treated with
RNAzap™. All solutions were made up with diethypyrocarbonate (DEPC)-treated
h2o.
2.5.1 RNA extraction
Total RNA was isolated from primary cortical cultures as follows: cells were
washed with lx PBS, lysed with Trizol reagent (1ml per 10cm2) and allowed to
incubate at room temperature for a minimum of 5 minutes to permit the complete
dissociation of nucleoprotein complexes. Chloroform was added to each sample,
mixed vigorously by hand then incubated at room temperature for a further 2-3
minutes before centrifugation at 12,000 rpm for 15 minutes at 4°C. The upper
aqueous phase containing RNA was transferred carefully into fresh tubes, and
RNA was precipitated with 500ul isopropyl-alcohol for 10 minutes. RNA pellets
were retrieved by centrifugation at 12,000rpm at 4°C for 10 minutes, washed with
75% ethanol, air-dried and resuspended in 30ul nuclease-free water. RNA samples
were incubated at 55°C for 10 minutes to thoroughly dissolve RNA.
The concentration and purity of RNA was assessed by measurement of optical
density as described in 2.1.1.11. Purity ratios ranged from 1.6 to 1.8 (75% to
100%). The integrity of RNA was also assessed by agarose gel eletrophoresis to
verify intact 28S and 18S ribosomal RNA.
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2.5.2 Synthesis and purification of riboprobes
Sense and antisense riboprobes were generated by in vitro transcription of
linearized insert-containing pGEM T-easy plasmids in reactions containing lx
transcription buffer, lOmM DTT, 40 units recombinant RNase inhibitor, ATP, CTP
and UTP mixture (0.5mM each), GTP (lOuM), 0.2-0.5ug linearized template DNA,
[a-32P]-GTP (3000Ci/mmol) and 20units of SP6 or T7 RNA polymerase. Reactions
driven by SP6 polymerase were incubated at 40°C whereas those using T7
polymerase were incubated at 37°C for 2 hours. Reactions were terminated by the
addition of 5 units RNase-free DNase and incubated for 15 minutes at 37°C.
Radiolabeled riboprobes for in situ hybridization were synthesized as above
except that [a-35S]-UTP was used.
2.5.3 Purification of riboprobe
Radiolabeled riboprobes were purified using DNA Nick™ columns according to
the manufacturer's instructions. Reaction mixtures were loaded onto
pre-equilibrated columns and allowed to penetrate into the columns by addition of
nuclease-free water (400ul). Purified samples were then eluted with further 200ul
nuclease-free water. The specific activity of each purified riboprobe was counted
using a Wallac 1450 Microbeta Plus liquid scintillation counter. The integrity of
each riboprobe was validated by resolution through 6% polyacrylamide gel
electrophoresis with 105cpm of riboprobe loaded
2.5.4 RNase Protection Assay (RPA)
RPAs were performed using the commercially available HybSpeed™ RPA kit.
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Total RNA (25ug) and carrier yeast tRNA (25ug) were precipitated in 0.1M
ammonium acetate, 2.5 volume of 100% EtOH and 2.5xl05cpm MR probe (MRa,
MRp or MRy) and lxl04cpm P-actin probe (internal control) at -20°C for a
minimum of 20 minutes. Precipitated RNA was collected by centrifugation at
13,000rpm for 15 minutes and resuspended in lOul hybridization buffer. Samples
were denatured at 95°C and subjected to intermittent vortexing until each pellet
had completely dissolved. Samples were hybridized at 68°C for 10 minutes to 1
hour then treated with 0.5unit RNase A and 20units RNase T1 at 37°C for 30
minutes with occasional agitation, followed by addition of 1.5 volumes of
inactivation/precipitation buffer (150ul) and 75ul ethanol and incubation at -20°C
for least 1 hour. Protected double-stranded RNA pellets were obtained by
centrifugation at 13,000rpm for 15 minutes at room temperature and resuspended
in 6ul polyacrylamide gel loading buffer. Samples were denatured at 95°C for 3
minutes, chilled on ice and loaded onto the gels as described in 2.1.2.
2.5.5 In situ hybridization
Cryostat coronal sections of frozen brain (12um) were cut and thaw-mounted onto
Superfrost™ microscope slides. Mounted sections were briefly air dried and
stored under desiccated conditions at -80°C until ready for use.
Fixation
Sections were allowed to warm to room temperature then fixed in ice-cold 4%
paraformaldehyde for 10 minutes. Slides were rinsed twice in lx PBS and
incubated in 0.1M triethanolamine for 10 minutes, washed again in lx PBS, then




Fixed sections were treated with lx prehybridization buffer, coverslipped and
incubated under humid conditions at 50°C for a minimum of 3 hours.
Hybridization mix comprised of 107 c.p.m. radiolabelled probe in lx hybridization
buffer and deionized formamide (12.5mM) was denatured at 75°C then chilled on
ice before DTT was added (lOmM). After prehybridization buffer was replaced
with hybridization mixture, slides were re-coverslipped and returned to the
hybridization oven for a further 16-18 hours.
Following hybridization, sections were washed three times in 2x SSC then treated
with RNase (0.09ug/ml) in RNase buffer at 37°C for 1 hour. Slides were washed
once in 2x SSC at room temperature then subjected to two stringent washes in
O.lx SSC at 60°C for 1 hour. Finally brain sections were dehydrated through an
ascending series of ethanol (50%, 70% and 90%) containing ammonium acetate
(0.3M), air dried then exposed to Kodak MR autoradiographic film for 2-3 weeks.
NTB2 photoemulsion and development of the slides:
Slides were exposed to photographic liquid emulsion to enable visualization of the
hybridization signal in the form of silver grains. All procedures were carried out in
the dark room under a safety light. Photographic emulsion was melted in a water
bath at 42°C and diluted with DEPC H20 (1:1 vol/vol). Slides were gently
immersed in the liquid emulsion then allowed to dry overnight at room
temperature. Dried slides were placed in light-tight boxes, wrapped in foil paper
and exposed for 3 weeks at 4°C.
Slides were brought to room temperature then developed in Kodak 19
photographic developer solution at 15°C. Developed slides were fixed in 20%
Kodak Fixative buffer for 5 minutes, rinsed with water then air-dried at room
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temperature. Developed slides were counter-stained with 1% pyronin Y and
mounted in DEPEX mountant.
For each hippocampal subfield, mRNA expression levels were quantified by
measuring the mean total intensity (pixels) of silver grains per neuron per
subregion by computer assisted quantitative grain counting using an MCID M4
image analysis system. For each animal, 3 adjacent sections were analyzed with
20 neurons measured randomly per subfield. The results were analysed and
obtained by the investigator blinded to experimental condition.
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2.5.6 Materials
Table 2-10 Materials for RNA analysis, RPA and in situ hybridization
Radioactive materials and riboprobe generation
5'-[a-32P]-rGTP 3000Ci/mmol Amersham
5'-[a-35S]-rUTP 3000Ci/mmol Amersham
Liquid scintillant Zinsser Analytic
Nick™ columns Amersham





Diethyl pyrocarbonate (DEPC) Sigma-Aldrich
RPA
HybSpeed™ Ribonuclease protection assay Ambion
kit
(3-actin antisense plasmid templates Ambion
Whatman paper 3MM Whatman
Autoradiograph film (Kodak Biomax MS) Sigma-Aldrich




















Sonicated salmon sperm DNA Sigma-Aldrich
Dextran sulphate salt Sigma-Aldrich
Kodak autoradiography emulsion VWR
Pyronin Y Anachem
DEPEX Fluka
Superfrost plus micro slide BDH laboratory
Autoradiograph film (Kodak Biomax MR) Sigma-Aldrich
2.6 Data analysis
Blinded assessment was carried out for obtaining and analysing the results from
reporter gene assays, RPA and in situ hybridization. All the data were represented
as the mean ± S.E.M for the number of experiments indicated. Statistical analysis
was performed by one-way ANOVA for the comparison in all experiments except
that two-way ANOVA was carried out for in situ hybridization followed by




Table 2-11 List of equipments
Temperature-controlled hypoxia chamber Wolf laboratories Ltd
Nitrogen (oxygen free) BOC gases
Hoeffer vertical gel system (for RPA) Bright Instruments Ltd
Single-tube Luminometer Berthold Technologies GmbH&
Co.
Mode 583 gel drier Bio-Rad Laboratories
Cryostat Leica Microsystems
Fuji Film FLA-2000 phosphorimager Sigma-Aldrich
Fuji BAS phosphorimager screen Sigma-Aldrich
MCID M4 image analysis system MCID Research Imaging, Canada
Hybridization oven Weiss-Gallenkamp
Gene Quant RNA/DNA calculator Pharmacia
Eppendorf bench top microfuge Kendro
Wallac 1450 Microbeta Plus liquid
scintillation counter
Perkin and Elmer
Thermal cycler Techne Inc
Orbital shaking incubator Weiss-Gallenkamp
Microbiology Incubator Weiss-Gallenkamp
J2-MC centrifuge (mini- and maxi-prep) Beckman Coulter
Horizontal Electrophoresis apparatus Bio-Rad Laboratories
Optical light microscope Zeiss
Optimal TLX ultracentrifuge Beckman Coulter
UV transilluminator Uvitec Ltd






5M NaCl 146g NaCl was dissolved in 400ml DEPC H20 and
the volume was leveled up to 500ml
5M K acetate Dilute 60g potassium acetate. 11.5ml of glacia acetic
acetate in 28.5ml H20
5Ox TAE 121 g Tris, 28.5ml glacial acetic acid and 50ml 0.5M
EDTA (pH8.0) were dissolved in 500ml dH20.
lOx TBE 108g Tris, 55g Boric acid, 40ml of 0.5M EDTA were
dissolved in 1L dH20
Tris-EDTA (TE) lOmM Tris-HCL (pH8.0), 0.1mM EDTA
DNA loading buffer 10 mM Tris-HCl (pH 7.5), 0.15% orange G, 0.03%
xylene cyanol FF, 60% glycerol, 60 mM EDTA.
4% Paraformaldehyde 2.4g NaH2PC>4 and 11.35g Na2HPC>4 were dissolved
in 800ml DEPC H20 at 80°C. 40g paraformaldehyde
was added to the solution until completely dissolved.
The volume was adjusted to 1L and kept at 4°C prior
to use.
0.5 M EDTA 800ml DEPC H20 was added to 186.1 g EDTA pH




121 .lg Tris was added to 800ml water. pH was
adjusted to 8.0 or 7.5 with concentrated HCL and the
volume to 1000ml with water
lOx PBS 80g NaCl, 29g Na2HP04, 2g KH2P04 and 2g KC1
were dissolved in 900ml DEPC H20 first. The
volume was adjusted to 1L and then autoclaved
0.1 Triethanolamine 13.3ml triethanolamine was added to 800ml DEPC
H20. pH was adjusted to 8.0 with HCL and the
volume adjusted to 1L.
1M DTT solution 0.3g DTT was dissolved in DEPC H20.
10M NaOH 40g NaOH was dissolved in 100ml dH20.
DEPC H20 dH20 treated with 0.1% diethylpyrocarborate and left




1.2M NaCl, 20mM Tris (pH7.5), 2x Denhardt's
solution, 2mM EDTA, lmg/ml salmon testis DNA
and 0.2mg/ml Yeast tRNA in 10ml DEPC H20
2x hybridization buffer 0.2g/ml Dextran sulphate, 1.2M NaCl, 20mM Tris
(pH7.5), 2x Denhardt's solution, 2mM EDTA,
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0.2mg/ml salmon testis DNA and 0.2mg/ml Yeast
tRNAin 10ml DEPCH20.
GTE 50ml glucose, 25mM Tris-HCL (pH8.0), 10ml EDTA
10% SDS lOg SDS was added into 80ml dH20 and heated to
60°C until completely dissolved. pH was adjusted to
7.5 and the volume was to 100ml with dH20.
1M MgS04 Dissolve 12g MgS04 in 80ml dH20 and the volume
was adjusted to 100ml.




0.359g Tricine, 0.514g DTT, 0.2M EDTA, 2mM
MgC03, 5mM MgS04 and lOmg Coenzyme A were
in 50ml dH20.
Luciferase lysis buffer 25mM Tris (pH8.0), 2mM DTT, 1% Triton X100,
10% glycerol
RPA gel loading buffer
(provided by Ambion)
95% formamide/0.025% xylene, cyanol/0.025%
bromophenol blue, 18 mM EDTA, 0.025% SDS
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Chapter 3
PROMOTER ACTIVITY OF THE MINERALOCORTICOID
RECEPTOR VARIANTS IN RESPONSE TO DIFFERENT
CELLULAR STRESSORS
3.1 Introduction
For any given gene, transcription is primarily regulated by the activity of its
promoter. It is now increasingly recognized that many genes have multiple
promoters which generate distinct and uniquely regulated transcripts from a single
gene (Landry et al. 2003). Previous studies have revealed that the rat MR gene
gives rise to three MR mRNA variants (a, P, y) each encoding alternative
5'-untranslated regions. Transcription of each mRNA variant appears to be under
the control of its own promoter. Similarly, the human MR gene generates two
mRNA variants under the control of two separate promoters (PI and P2) (Zennaro
et al. 1996). Each of the MR variants has been shown to be expressed in a tissue-
and development-specific manner (Kwak et al. 1993; Vazquez et al. 1998;
Pascual-Le Tallec et al. 2004). A fragment of the rat MRa promoter was
successfully cloned and found to respond to corticosteroids in a neuronal cell line
(Castren et al. 1993). However, the exact function of each exonl variant or other
factors which regulate MRa, MRp or MRy promoter activity have yet to be
identified.
Since MR expression is increased in response to cell injury (Macleod et al. 2003)
but how this is regulated at the transcript level is not known, this chapter focuses
on how injury-induced MR is regulated at the promoter level. Experiments were
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designed to specifically answer the following:
(i) If the MR promoters are differentially regulated by cellular stress.
(ii) If promoter activity is specific to certain types of cellular stressor.
(iii) If promoter activity in response to cellular stress is dependent on cell
type.
3.2 Results
3.2.1 Optimisation of experimental conditions
The promoter activity of each rat MR variant was investigated using a luciferase
reporter assay whereby each promoter fragment was placed upstream of the
pGL-3 firefly luciferase reporter construct and co-transfected with pCHHO
encoding (3-galactosidase into PC12 cells. The PC12 clonal cell line is derived
from a pheochromocytoma of the rat adrenal medulla (Greene et al. 1976). These
cells were chosen because they undergo differentiation in response to nerve
growth factor (NGF): they cease proliferation, extend neurites and express
neuronal markers associated with sympathetic neurons (Greene et al. 1976). As
such they have been used extensively as a model system for primary neuronal
cells. Here, both undifferentiated and differentiated PC12 cells were used as
models to compare the activity of the MR promoters in essentially two different
cell types (non-neuronal and neuronal-like).
3.2.1.1 Establishment of conditions for PC12 cell differentiation
The conditions for differentiating PC12 cells were first established using three
different methods to verify the transition of PC12 cells from an undifferentiated to
differentiated state: (i) observation of morphological changes by light microscopy,
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(ii) measurement of the rate of cell proliferation and (iii) immunohistochemical
detection of the sympathetic neuronal differentiation marker tyrosine hydroxylase.
Morphological changes:
Undifferentiated PC12 cells were cultured in serum-free DMEM with lOOng/ml
NGF for 6 days, with NGF replenished on the 3rd day. As shown in Fig 3-1,
undifferentiated PC12 cells underwent dramatic morphological changes during the
process of differentiation. Undifferentiated PC12 cells display a round or elliptical
shape (Fig 3-1 A) with no extensions from the cell body. Exposure to NGF caused
cells to develop neurite-like projections within 24 hours. After 3 days of exposure
to NGF, these projections extended considerably to form connections with other
cells and eventually gave rise to an apparent neuronal network. This phenotype
remained stable throughout the 7-day experimental time frame. Based on these
microscopic observations, this suggests that undifferentiated cells accomplish
differentiation by 3 days.
Cell proliferation
Since PC12 cells cease to proliferate when they undergo NGF-induced
differentiation, measuring the rate of proliferation provides a useful indication of
the differentiation status of these cells. In this experiment, the rate of cell
proliferation was measured using the MTS assay which is based on the ability of
mitochondria to metabolically convert the compound MTS [3-(4,5-dimethylthiazol
-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] into the
formazan product which is then quantified colorimetrically. The intensity of the
converted formazan is directly proportional to the number of living cells. As Fig
3-2 shows, the rate of production of the converted formazan in PC12 cells either in
the presence or absence of NGF was similar over the first 3 days, indicating there
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was no significant difference in cell proliferation. However by day 4, the amount
of converted formazan in undifferentiated cells was significant higher (36%±1.5%;
pcO.OOl) compared to differentiated cells. This increase was even more profound
on day 5 (61%±0.3%; pcO.OOl) and day 6 (157%±1.8%; p<0.001). Whereas there
was no difference in formazan production between NGF treated PC12 cells at day
3 (0.48±0.01) and day 4 (0.55±0.02), 5 (0.52±0.02) or 6 (0.45±0.02). The data
indicated NGF-treated cells ceased proliferation and terminally differentiated by
day 3.
Immunohistochemical detection of tyrosine hydroxylase
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthesis of
catecholamines and is often used as a marker for differentiated PC12 cells. To
confirm NGF-treated PC12 cells had undergone differentiation,
immunohistochemical detection of TH was carried out and the amount of staining
was compared between undifferentiated and differentiated cells. As shown in Fig
3-3A, there was little staining in undifferentiated PC12 cells. However, intense TH
immunoreactivity was observed 3 days after PC12 cells were exposed to NGF in
particular those had neurite extensions (Fig3-3B and Fig3-3C). This suggests
PC12 cells had differentiated into neuronal-like cells expressing tyrosine
hydroxylase.
Taken together, it demonstrates that undifferentiated PC12 cells accomplished
differentiation by day 3 since addition of lOOng/ml NGF. Therefore, all the
experiments using differentiated PC12 cells were carried out on day 3.
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Fig 3-1. Progression of morphological changes of PC 12 cells with
exposure to NGF for 6 days. (A) Undifferentiated PC 12 cells were seed
on day 0. By day 1 cells had begun to sprout neurites and by day 3 were
morphologically distinct showing cell-cell connections (B)-(D). This


















Fig 3-2. Rate of cell proliferation in PC 12 cells incubated in the presence
or absence ofNGF, measured by MTS assay. Undifferentiated PC 12 cells
were exposed to lOOng/ml NGF for 6 days, with NGF replenished on 3rd
day. Cells exposed to NGF showed an increase in absorbance between
dayO and day3, but this was not further increased after day4.
Undifferentiated cells showed a continuous increase in absorbance over
the timescale measured. Values represent the mean ± S.E.M. ***p<0.001.
n=4 independent experiments with each timepoint performed in
triplicate.
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Fig 3-3. Immunohistochemical staining for tyrosine hydroxylase(TH) in
undifferentiated and differentiated PC 12 cells. (A) Undifferentiated PC 12
cells with mouse anti-TH monoclonal antibody (1:500 dilution). (B)
Differentiated PC 12 cells with mouse anti-TH monoclonal antibody
(1:500 dilution), x20 times magnification (C) Differentiated PC12 cells
with anti-TH monoclonal antibody (1:500 dilution), *20 magnification.
(D) Negative control: differentiated PC 12 cells incubated without mouse
anti-TH monoclonal antibody.
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3.2.1.2 Selection of cell stressors
Previous work had demonstrated that MR induction occurred both in vitro when
primary neuronal cultures were exposed to sub-lethal concentrations of
staurosporine and in vivo in hippocampal neurons when animals had been
subjected to hypothermic transient global cerebral ischaemia (Macleod et al.
2003). Therefore to determine how these insults might regulate MR, their effects
on alternate MR promoter activity were investigated in both undifferentiated and
differentiated PC12 cells. Ischaemia was mimicked in vitro by oxygen-glucose
deprivation (OGD). The effects of OGD and hypothermia at 33°C alone and in
combination (OGD&hypothermia) were studied. Both oxidative stress and
hypersecretion of glutamate contribute to ischaemic damage therefore the effects
of hydrogen peroxide (H202) and glutamate in the form of NMDA on MR
regulation were also investigated.
3.2.1.3 Dose (time)-dependent effects of cellular stressors on cell viability
To determine the most suitable concentration or exposure time of each cell stressor
for subsequent use in the promoter activity assays, dose- or time-response curves
were performed. Release of lactate dehydrogenase (LDH) was used as the measure
of cell damage. The concentration or time of exposure causing 20% of maximal
cellular LDH release (representing sub-lethal challenge) was determined for each
of the cell stress conditions.
Staurosporine
Undifferentiated and differentiated PC12 cells were exposed to staurosporine
(10"9M to 10"5M) for 24 hours and the amount of LDH released into the culture
medium was measured. Values were calculated as a percentage of total LDH,
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expressed relative to non-stressed controls (defined as 0) and plotted using a
Sigmoidal dose-response equation. As shown in Fig3-4 (A), in undifferentiated
PC12 cells, lOuM staurosporine caused 65% LDH release in undifferentiated cells
whereas this concentration caused 100% LDH release in differentiated cells. The
EC20 was calculated to be lOnM in undifferentiated cells (correlation coefficient
r2=0.8185) and 3nM in differentiated cells (r2=0.8484). As illustrated in Fig 3-4,
the dose-response curve for differentiated cells was shifted to the left with respect
to undifferentiated cells. However, there was no significant difference between the
two dose-response curves (F=1.49, p=0.167, two way ANOVA), suggesting that in
fact differentiated PC12 cells were no more susceptible to staurosporine than
undifferentiated cells.
Hydrogen peroxide
Undifferentiated and differentiated PC12 cells were exposed to H2O2
(lOuM-lOmM) for 24 hours and data was expressed as described above. As shown
in Fig 3-5, maximum cell damage (100% LDH release) was induced at ImM
(10"3M) in undifferentiated cells and 3mM in differentiated cells. The EC20
calculated by curve fit was lOOuM in undifferentiated cells (r2=0.9710), and
300uM in differentiated cells (r2=0.9574). In addition, the dose-response curve for
undifferentiated cells was shifted significantly to the left with respect to
differentiated cells (F=18.612, p<0.001, two-way ANOVA), indicating that
undifferentiated cells were more susceptible to damage caused by hydrogen
peroxide.
NMDA
Undifferentiated and differentiated PC12 cells were exposed to a range of
concentrations [10"5M to 10"2M] of NMDA and the amount of LDH released was
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measured 24 hours later. Results showed that there was no difference in the
amount of LDH in the culture medium between undifferentiated, differentiated
cells and vehicle treated cells at any concentration of NMDA. Therefore, the
experiments determining the effects of NMDA on promoter activity were not
carried out.
OGD
Undifferentiated PC12 cells were cultured in glucose-free DMEM medium in a
hypoxic chamber (1% O2, 5% CO2 and 94% N2) at 37°C over 6 different time
points (1, 2, 4, 6, 12 and 24 hours). Cells were returned to normal culture
conditions of glucose and oxygen in a standard cell culture incubator for the
remaining 24 hours. As shown in Fig 3-7(A), for undifferentiated cells, compared
to the control, there was a significant increase in LDH release at 4 (5.76%±0.66%,
p<0.01) and 6 hours (5.09%±0.64%, p<0.01) but not at 12 or 24 hours.
The effects of OGD on the extent of LDH release in differentiated PC12 cells
were assessed under two different conditions: either in the presence (+NGF) or
absence of NGF (-NGF). As show in Fig 3-7(B), basal LDH release was 11.5% in
+NGF group and 31.7% in -NGF group. There was no significant difference in
LDH release either in the -NGF or +NGF group at the 1, 2 or 4-hour time point
compared to the 0-hour control group. However, exposure to OGD for 6 hours
caused significantly increased cell damage to 36.2% (p<0.05) in +NGF group and
58% (p<0.05) in -NGF group respectively in comparison to the non-OGD control.
And exposure to OGD for 24 hours caused a greater LDH release (50%; p<0.01)
in differentiated cells in the +NGF group, whereas in the -NGF group this was not
significantly different from the 6-hour timepoint.
The overall magnitude of LDH release in both +NGF and -NGF groups was
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calculated to be approximately 25%. However, the level of LDH release in 0-hour
control group was significantly higher in the -NGF group compared to the +NGF
group (p<0.001), suggesting that withdrawal of NGF itself appears to affect the
viability of the cells. To this end, the -NGF group was excluded from subsequent
promoter activity to avoid any confounding effects of NGF withdrawal. Therefore,
cells cultured in the presence of NGF and exposed to 6-hour OGD were the
chosen conditions for MR promoter studies in both undifferentiated and
differentiated cells.
Hypothermia and OGD&hypothermia
For the purposes of continuity with the OGD experiments, the effects of 6-hour
exposure to hypothermia and OGD&hypothermia in undifferentiated and
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Fig 3-4. Dose-dependent effects of 24-hour exposure to staurosporine in
undifferentiated and differentiated PC 12 cells. Data was normalized with
respect to the control group and plotted using the Sigmoidal
dose-response equation. The EC20 was lOnM in undifferentiated cells and
3nM in undifferentiated cells. There was no significant difference
between the two curves by two way ANOVA (F=1.49, p=0.167). Values





Fig 3-5. Dose-dependent effects of 24-hour exposure to hydrogen
peroxide in undifferentiated and differentiated PC 12 cells. Data was
normalized with respect to the control group set and plotted using a
Sigmoidal dose-response equation. The EC20 was lOOuM in
undifferentiated cells and 300uM in differentiated cells. There was a
significant difference between the two curves by two way ANOVA
(F=l8.612, p<0.001). Values represent the mean ± S.E.M. n=4
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Fig 3-6. Dose-dependent effects of 24-hour exposure to NMDA in
undifferentiated and differentiated PC 12 cells. Data was normalized with
respect to control group and plotted using the Sigmoidal dose-response
equation. There was no effect of NMDA on LDH release. Values












Fig 3-7. Time-course for OGD-induced LDH release in undifferentiated
(A) and differentiated PC 12 cells (B). LDH release was significantly
higher at 4-hour and 6-hour exposure to OGD in undifferentiated cells
(p<0.01) compared to 0 hr. At 6hr LDH release was significantly higher
in differentiated PC 12 cells -NGF (55%) than +NGF (35%) Values
represent the mean ± S.E.M. *P<0.05; **P<0.01 vs 0 hour control. n=6
independent experiments, each performed in triplicate.
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3.2.2 Generation ofMRP and MRj promoter constructs
The recombinant plasmid pMRa containing a 1.5kb fragment of the MRa
promoter was generated by Dr. Maija Castren, University of Kupio, Finland
(Castren et al. 1993). To generate the plasmids pMR(3 and pMRy, the putative
promoter fragments of MRP and MRy were amplified from rat genomic DNA
respectively by PCR using high-fidelity DNA polymerase. PCR products were
visualized by agarose gel electrophoresis and fragments generated were of the





Fig 3-8. PCR amplification of the MRP and MRy promoter fragments.
Lane 1 shows the MRP PCR product at the predicted size of 300bp and
lane 4 shows the 1.7kb MRy PCR product. Lane 2 = 1 OObp ladder; lane 3
= 1Kb ladder.
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3.2.3 Effects of cellular stressors on alternate MR promoter
activity in undifferentiated PC12 cells
Each promoter plasmid was co-transfected into undifferentiated PC12 cells with a
P-galactosidase-encoding plasmid to enable normalization of the transfection
efficiency. Promoter activity was calculated as a mean ratio of luciferase to
p-galactosidase activity and expressed relative to the promoterless pGL-3 vector.
All stressors with the exception of NMDA were tested for their effects on
promoter activity at the EC20 derived from section 3.2.1.2.
3.2.3.1 Basal activity
The mean basal activity (taken from the whole experimental set) of the MRa
promoter was 3.42±0.37 fold higher than the promoterless vector pGL3 in
undifferentiated PC12 cells, whereas MRP promoter displayed the lowest basal
activity at 0.19±0.01 fold of pGL3 while MRy was 1.75±0.13 fold greater than
pGL-3. It is noteworthy that although the actual values from each experiment were
different, the pattern was similar throughout (MRa>MRy>MR|3). (Tab 3-1)
3.2.3.2 Effect of cellular stressors
As shown in Fig 3-9, lOnM staurosporine significantly increased MRa promoter
activity (300%±33%, pcO.OOl) compared to vehicle but had no effect on either
MRp or MRy promoter activity. Exposure of undifferentiated cells to hydrogen
peroxide(Fig3-10), OGD(Fig3-ll), hypothermia(Fig3-12) or OGD&hypothermia
(Fig3-10) had no effect on MRa, MR(3 or MRy promoter activity.
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Fig 3-9. Effect of lOnM staurosporine on MR promoter activity in
undifferentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MR(3 or MRy promoter constructs and promoter activity of each
construct was determined and expressed as relative luciferase activity.
MRa promoter activity was significantly increased in the presence of
staurosporine (300% ±33%, p<0.001) compared to vehicle, while there
were no significant changes in MRP or MRy promoter activity. Values
represent the mean ± S.E.M. ***p<0.001. n=6 independent experiments
performed in triplicate
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Fig 3-10. Effect of lOOuM H2O2 on MR promoter activity in
undifferentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRP or MRy promoter constructs and promoter activity of each
construct was determined and expressed as relative luciferase activity. No
significant changes were observed for MRa, MRp or MRy promoter
activity. Values represent the mean ± S.E.M. n=5 independent
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Fig 3-11. Effect of OGD (6-hour) on MR promoter activity in
undifferentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRp or MRy promoter constructs and promoter activity of each
construct was determined and expressed as relative luciferase activity. No
significant changes were observed for MRa, MRp or MRy promoter
activity. Values represent the mean ± S.E.M. n=6 independent










Fig 3-12. Effect of hypothermia (6-hour) on MR promoter activity in
undifferentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRp or MRy promoter constructs and promoter activity of each
construct was determined and expressed as relative luciferase activity. No
significant changes were observed for MRa, MRp or MRy promoter
activity. Values represent the mean ± S.E.M. n=6 independent









Fig 3-13. Effect ofOGD&hypothermia (6-hour) on MR promoter activity
in undifferentiated PC 12 cells. PC 12 cells were transiently transfected
with MRa, MRP or MRy promoter constructs and promoter activity of
each construct was determined and expressed as relative luciferase
activity. No significant changes were observed for MRa, MR|3 or
MRy promoter activity. Values represent the mean ± S.E.M. n=6
independent experiments, each performed in triplicate.
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3.2.4 Effects of cellular stressors on alternate MR promoter
activity in differentiated PC12 cells
The efficiency of transfection in differentiated cells was found to be extremely
low in pilot studies, therefore to circumvent this problem, undifferentiated cells
were transiently transfected with each promoter construct and then exposed to
NGF for differentiation. Expression of constructs was stable for at least 7 days
following introduction of NGF (data not shown). Cells were subjected to the
different cell stress conditions on day 4 of differentiation and promoter activity
was measured 24 hours later as described for undifferentiated cells.
3.2.4.1 Basal activity
The mean basal promoter activity was calculated from all of the experiments
performed. Compared to the activity of the pGL-3 promoterless vector, MRa
promoter displayed the highest basal activity (17.68±1.5 fold), followed by MRy
(8.49±0.96 fold) and MRp (1.27±0.17 fold) in differentiated cells. This pattern of
basal activity was in accordance with undifferentiated cells. Furthermore, the basal
activity of each promoter in differentiated PC 12 cells was also significantly
increased compared to undifferentiated cells (p<0.001). (Table 3-1).
Table 3-1 Basal promoter activity of MRa, MRp and MRy in






MRa 3.42 ±0.37 17.68 ± 1.5 <0.001
MRp 0.19 ±0.01 1.27 ± 0.17 <0.001
MRy 1.75 ±0.13 =• 8.49 ± 0.96 <0.001
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3.2.4.2 Effect of cellular stressors on MR promoter activity in differentiated PC12
cells
Exposure to staurosporine (3nM) for 24 hours caused a significant increase in
MRa promoter activity compared to vehicle treated group (215.4%±22%, p<0.05)
(Fig 3-14). However, staurosporine had no effect on either MRp or MRy promoter
activity. As with undifferentiated PC12 cells, hydrogen peroxide (300uM) (Fig
3-15), OGD (6-hour) (Fig 3-16) or hypothermia (6-hour) (Fig 3-17) did not induce
significant changes in MRa, MRp or MRy promoter activity compared to vehicle
group.
However, exposure to OGD&hypothermia significantly increased MRa promoter
by 51% (p<0.001) compared to the control group (Fig 3-18). The promoter
activity of MRp was also increased significantly by 85% (p<0.05) while MRy
promoter activity was not affected by OGD&hypothermia at any level.
Overall, these results show that there is differential regulation of MR promoters in
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Fig 3-14. Effect of 3nM staurosporine on MR promoter activity in
differentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa. MRp or MRy promoter constructs, differentiated for 3 days and
promoter activity of each construct in the presence of staurosporine was
determined and expressed as relative luciferase activity. MRa promoter
activity was increased by 212.4%±31.4% (p<0.05) compared to vehicle
but neither MRp nor y promoter activity was affected. Values represent


















Fig 3-15. Effect of H2O2 (300uM) on MR promoter activity on
differentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRP or MRy promoter constructs, differentiated for 3 days and
promoter activity of each construct in the presence of H2O2 was
determined and expressed as relative luciferase activity in differentiated
PC 12 cells. No significant changes were observed for MRa, MRP or
MRy promoter activity. Values represent the mean ± S.E.M. n=5










Fig 3-16. Effect of OGD (6-hour) on MR promoter activity in
differentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MR(3 or MRy promoter constructs, differentiated for 3 days and
promoter activity of each construct exposed to OGD was determined and
expressed as relative luciferase activity. There were no significant
changes in MRa, MRfl or MRy promoter activity. Values represent the
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Fig 3-17. Effect of hypothermia (6-hour) on MR promoter activity in
differentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRP or MRy promoter constructs, differentiated for 3 days and
promoter activity of each construct exposed to hypothermia was
determined and expressed as relative luciferase activity. There were no
significant changes in MRa, MRp or MRy promoter activity. Values














Fig 3-18. Effect of OGD&hypothermia (6-hour) on MR promoter activity
in differentiated PC 12 cells. PC 12 cells were transiently transfected with
MRa, MRP or MRy promoter constructs, differentiated for 3 days and
promoter activity of each construct exposed to OGD&hypothermia was
determined and expressed as relative luciferase activity. MRa promoter
activity was significantly increased by 51% (p<0.001) and MRp
promoter activity was also significantly increased by 85% (p<0.05)
compared to control. No changes were seen in MRy promoter activity.
Values represent the mean ± S.E.M. *p<0.05; ***p<0.001. n=5-9
independent experiments, each performed in triplicate.
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3.3 Discussion
The aim of this chapter was to determine ifMR might be differentially regulated
at the promoter level in response to different types of cell stress and if this
regulation was specific to cell-type. The results are summarized in Table 3-2.
Table 3-2. Effect of different types of cell stress on MRa, MRP and MRy
promoter activity: comparison between undifferentiated and differentiated
PC 12 cells
Undifferentiated PC 12 Differentiated PC 12
MRa MRP MRy MRa MRp MRy





no change; | significant increase
Data in this chapter demonstrated that there is indeed differential regulation ofMR
variants in response to cell stress. This up-regulation was not a generic response
since only some but not all types of cellular stressors investigated caused
induction ofMR variant promoter activity.
Staurosporine is commonly used as a general apoptosis-inducing agent (Jacobsen
et al. 1996; Wiesner et al. 1996; Fitzgerald et al. 2007). lOnM staurosporine
caused a significant increase in MR expression in primary cortical culture
(Macleod et al. 2003). In this experiment, MRa promoter activity was
significantly increased in response to staurosporine, suggesting the total MR
induction in primary cortical culture was primarily mediated by MRa. In addition,
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the effect of staurosporine on MR expression does not depend on a specific
cell-type since this was observed in both undifferentiated and differentiated cells.
OGD&hypothermia significantly increased both MRa and MRp promoter activity
in differentiated PC12 cells, whereas neither OGD nor hypothermia alone had
effects on any of the MR promoters. These observations corroborate previous
findings that MR expression can be induced by hypothermic but not normothermic
ischaemia in vivo (Macleod el al. 2003). It is known that mild to moderate
hypothermia generally reduces ischaemic damage in the brain (Busto et al. 1989;
Buchan et al. 1990; Baker et al. 1995). The exact mechanisms of hypothermic
neuroprotection is still not clear, but the expression of some genes are altered by
hypothermia (Ohta et al. 2007), some of which are known to be neuroprotective,
indicating that hypothermia itself triggers an endogenous survival response. This
work suggests that MR induction may form part of the neuroprotective effects of
hypothermia. The differential regulation of transcription through alternate
promoter usage in the context of brain injury is not unique to MR, since it is
known that other genes encoding protective proteins such as BDNF also undergo
differential regulation in response to cerebral ischaemia in hippocampal and
cortical neurons through stimulation of at least two different promoters (Tsukahara
et al. 1998).
More importantly, the induction of MRa and MR(1 promoter activity by
OGD&hypothermia was largely confined to neuronal-like cells since this was only
observed in differentiated PC12 cells. This demonstrates that such induction of
MR is subjected not only to the type of cell stress but also to the type of cell.
While the MRa promoter responds to more varied stimuli in different cell types,
the MRp promoter appears to be specifically activated in neuronal-like cells to
neuronally relevant stimuli OGD&hypothermia. This has important implications
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and identifies the MRP promoter as a potential target for clinical interventions for
conditions of cerebral ischaemia. The goal would be to enhance MR expression
specifically in neurons, because the activation of MR in other cell type or tissue
may be detrimental. For example activation of MR in the vasculature vessels leads
to vascular remodelling (1.4.5.3) involving reduced lumen and outer diameters but
normal vascular wall thickness (Dorrance et al. 2006) and causing hypertension
which itself is a risk factor for ischaemia (Hilleman et al. 2004; Sokol et al. 2004).
Moreover, increased MR signalling in the cardiac myocytes is associated with
cardiac hypertrophy and fibrosis (Takeda et al. 2002). Although the MRp
promoter was not altered by OGD&hypothermia in undifferentiated cells, it will
be necessary to carry out further studies to exclude the possibility that the MRp is
stimulated in other cell types by clinical relevant conditions of neuronal stress.
Interestingly, the MR promoters showed different basal activities both in
undifferentiated and differentiated PC12 cells, displaying an order from the
highest to lowest MRa>MRy>MRp. Only regulation of the MRa. promoter has
been reported in the literature, which showed an increased activity in response to
corticosterone and progesterone in a rat neuroblastoma cell line (Castren et al.
1993; Castren et al. 1995; Castren et al. 1995), however there are no studies
reported of the regulation of either the MRp or MRy promoter.
Since the distance between MR exonip and exonly is only 300bp, the promoter
fragment of MRP was initially generated to span this short region. The basal
promoter activity of MRP was lowest of the three promoters in both
undifferentiated and differentiated PC12 cells. This was probably attributable to
lack of the necessary enhancers within this 300bp DNA fragment. A quick analysis
of putative binding sites suggested that there was no TATA box or other classical










Fig 3-19. Illustration of MRP promoter region. Putative transcriptional
factor binding sites are predicted using online software Genomatix
(http://www.genomatix,de/). A transcriptional repressor is located at
-185bp, as shown in square; +1: transcription initiation site. Underline:
Exon.
repressor was found upstream at -185bp from the transcription initiation site
(Fig3-19), which may also account for the low activity of MRP promoter. 1.7kb
rat MRy promoter fragment showed a substantial basal activity, suggesting it was
fair active in a biological context.
The basal promoter activity of each of MR variants in differentiated cells was
significantly higher than undifferentiated cells (Tab 3-2). This implied all of MR
variant promoters were switched on in neuronal-like cells but repressed to some
extent in non-neuronal cells. This is not novel since some other genes have been
reported to be differentially expressed in a cell type-specific manner, e.g. BDNF
(Hohl et al. 2005). MRp and MRy mRNA levels were highly expressed in
developing hippocampus but decline postnatally (Vazquez et al. 1998), suggesting
an induction of its own promoter may be utilized. During the transition of
phenotype of PC 12 cells from undifferentiated to neuronal-like differentiated state,
MR variant promoters may also be induced.
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The PC12 cell line itself is a useful tool to compare the activity of the same
promoter in two different cell types because of its ability to differentiate into
neurite-bearing cells resembling mature sympathetic neurons (Greene et al. 1976;
Greene 1978). These cells have been used extensively as a neuronal model for
studying neuropathophysiological mechanisms (Rukenstein et al. 1991; Ferrari et
al. 1993; Maroto et al. 1997; Levites et al. 2003; Qing et al. 2003), including
those associated with ischemia (Tabakman et al. 2005; Hillion et al. 2006) and
were used here to specifically test MR promoter activity due to the ease of
transfection of promoter constructs. Primary neuronal cultures would be the ideal
model but are notoriously difficult to transfect because they are terminally
differentiated and indeed, initial pilot studies revealed that differentiated PC12
cells themselves were difficult to transfect. One way around this was to transfect
the PC12 cells and then to differentiate them.
LDH is a stable cytosolic enzyme and released into culture medium when the
integrity of cell membrane is damaged (Korzeniewski et al. 1983). Measurement
of released LDH can directly reflect the severity of cellular damage quantitatively.
However, it is not an ideal assay for measurement of apoptosis, since LDH is not
an apoptotic marker protein. In this study, the optimal dose or time point for
"stressing" cells was determined by measurement of cell damage (membrane
integrity) instead of apoptosis. This is because cell damage is a better index
reflecting the concept of "cellular stress", which ranges from the initial damage to
membrane integrity to the final stage cellular death, whereas apoptosis is only one
of those events.
6-hour OGD caused a significant increase in cell damage from basal level 11.49%
to 35% in differentiated PC12 cells in the presence of NGF, suggesting
differentiated cells were sensitive to this neuronal-specific insult. Although there
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was a significant increase in undifferentiated cells at 4- and 6-hour exposure, the
absolute percentage of cell damage was too small, at approximately 5-6%. It is
assumed that this did not mount a profound stressful signalling, which might
explain why OGD or OGD&hypothermia failed to induce any effect on MR
variant promoters in undifferentiated cells. In addition, it is noteworthy that the
PC12 cells do not model neurons entirely but lack certain intrinsic properties of
neurons. For example, the overactivation of NMDA receptor has been stated as
one of the major processes in ischaemic neuronal death in vivo and in vitro
(Dingledine et al. 1999; Goebel et al. 1999; Lipton 1999). In this study, NMDA
failed to achieve any level of cell damage in either undifferentiated or
differentiated PC12 cells, which suggested this type of cell system still lacks some
neuronal properties. The failure of NMDA may be attributed to the absence of
functional NMDA receptor in PC12 cells (Gerlach et al. 2002; Edwards et al.
2007), despite the presence of subunits in PC12 cells (Sucher et al. 1993; Casado
et al. 1996).
3.4 Concluding remarks
In conclusion, MR is differentially regulated at the promoter level by different
conditions of neuronal stress which appears to depend on the cell type. The MRa
promoter responds to both non-neuronal and neuronal-like stimuli whereas the
MRp promoter is specifically activated by neuronally relevant stimuli in
neuronal-like cells. The MRy promoter however does not respond to any of the
cell stressors. As far as is known this is the first evidence for a mechanism
regulating the MRP promoter and suggests that regulation of MR via the MRP
promoter activity specifically serves to enhance neuronal survival. Thus targeting





MESSENGER RNA LEVELS OF THE MINERALOCORTICOID
RECEPTOR VARIANTS IN PRIMARY CORTICAL CULTURE
IN RESPONSE TO CELLULAR STRESSORS
4.1 Introduction
Results obtained from Chapter 3 show that different types of cell stress
differentially affect the activity of the MR variant promoters and this is dependent
on the differentiation status of the PC 12 cells. While the promoter activity
provides an indication of the changes in gene expression, the assay itself is
artificial using a small portion of the actual promoter and enhancer region of a
given gene which does not truly reflect changes in the abundance of the gene.
Furthermore, although differentiated PC 12 cells are considered a model of
neuronal cells there are several limitations particularly as they are not derived
from the central nervous system and do not possess all the characteristics of
neuronal cells. Induction of total MR mRNA in response to cell stress (exposure to
staurosporine) has been described previously (Macleod et al. 2003), however
neither the effects of OGD, hypothermia or OGD&hypothermia on total MR
mRNA nor their effects on MR variant mRNA expression have been explored.
Therefore this chapter considers the effect of different types of cell stress on MR
variant mRNA expression in primary cortical neuronal culture. These cultures
provide a more suitable model than differentiated PC 12 cells because they are
derived from the embryonic brain tissue and express endogenous MR. Therefore
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the aims of this chapter were to investigate:
(i) Which MR variant mRNA level(s) is/are altered by cellular stressors
in rat primary cortical culture.
(ii) If total MR expression is changed due to such altered MR variant(s)
in response to the cellular stressors.
4.2 Results
4.2.1 Optimisation
Primary cortical cultures were generated as described in Materials & Methods and
as with PC12 cells, experimental cell culture conditions were optimised by
performing time-response curves. Given that changes in promoter activity were
observed primarily in response to OGD&hypothermia and not to
chemically-induced cell stress other than staurosporine, only the effects of OGD,
hypothermia, OGD&hypothermia and staurosporine on MR variant mRNA
expression were investigated by Ribonuclease Protection Assay (RPA).
4.2.1.1 Characterization of primary cortical culture
To determine the proportion of neurons in a typical primary cortical culture
preparation, immunohistochemistry was performed using an antibody against the
neuronal marker microtubule-associated protein 2 (MAP-2) and an antibody
against the glial marker glial-fibrillary acidic protein (GFAP). As shown in Fig
4-1, a greater proportion of cells were stained with MAP-2 (Fig 4.1A) compared
to GFAP (Fig. 4.IB). To determine the proportion of neurons to glia, the number
of stained neurons or glia was divided by the total number of the cells in any
given culture well. Unstained cells were clearly visible under phase-contrast
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Fig 4-1. Immunohistochemical staining for MAP-2 (A) and GFAP (B) in
primary cortical culture at day 14. Incubation in the absence of primary
antibody (MAP2 or GFAP) served as negative control (C). Stained cells
were counted and expressed as a percentage of the total cells for each
given field. Values represent the mean ± S.E.M , ***p<0.001, n = 4
independent experiments with each performed in duplicate.
Magnification X 20.
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microscopy. As shown in Fig 4-l(D) a typical preparation of primary cortical
culture is predominantly composed of approximately 80% neurons and 20% glia.
4.2.1.2 Time-dependent effects of cellular stressors on cell viability
The effects of OGD and OGD&hypothermia over 24 hours on cell viability in
primary cortical culture were assessed by measurement of the amount of LDH
release as described in Chapter 3 to identify a suitable exposure time which caused
sub-lethal damage (-20% LDH release). Both the effects of OGD with and
without a period of recovery to a total of 24 hours which mirrors so-called
reperfusion in vivo, on LDH release were evaluated. The concentration of
staurosporine used was lOnM since this concentration has previously been shown
to induce total MR mRNA and protein (Macleod et al. 2003).
OGD without recovery
Primary cortical neurons were cultured in glucose-free DMEM medium in a
hypoxic chamber (1% 02, 5% CO2 and 94% N2) at 37°C over 6 different time
points (1, 2, 4, 6, 12 and 24 hours). Cell damage was measured immediately after
the end of each time point. As shown in Fig 4-2, the basal level of LDH release in
primary cortical culture was 12.37%±1.85%. Both 4-hour and 6-hour exposure to
OGD caused a significant increase in LDH release (23.28%±3.45%, p<0.05;
27.63%±2.35%, p<0.01) compared to the controls. The greatest amount of LDH
released was obtained after 24-hour exposure to OGD (54.49%±4.85%, p<0.001).
Since there was no significant difference between 4-hour and 6-hour time points
(p=0.317), the latter was chosen as the exposure time for OGD insult which
allowed a longer period for the potential changes of the MR variant transcripts.
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6-hour OGD with recovery
In Chapter 3, PC12 cells were returned to normal culture conditions following
exposure to OGD. Accordingly, the effects of OGD followed by recovery on LDH
release were also assessed in primary cortical culture. Based on the optimal
exposure time for OGD, 5 time points (0.5,1, 2, 4 and 18 hours) for recovery were
chosen following 6-hour OGD treatment. In Fig 4-3, a 30-minute recovery period
caused 41%±3.33% LDH release, significantly higher than 6-hour OGD without
recovery (27.63%±2.35%, p<0.05). This became more profound with the longer
recovery time such that an 18-hour recovery period resulted in 83.51%±1.5%
LDH release. This suggests that any amount of recovery causes additional damage
and therefore might confound any changes seen with MR expression and in line
with previous experiments (Macleod et al. 2003), therefore RNA was extracted
immediately from primary cortical culture for analysis following a 6-hour
exposure to OGD.
OGD&hypothermia
The effects of different periods of exposure to OGD&hypothermia on LDH
release was also evaluated in primary cortical culture. Basal LDH release in
controls was 13.68%±1.59%. Exposure to OGD&hypothermia over 4 time points
(1-6 hours) did not result in any significant changes compared to controls.
However, 16-hour (22.35%±0.38%, p<0.01) and 24-hour (23.22%±0.31%,
p<0.001) exposure to OGD&hypothermia caused a significant increase in LDH
release in comparison to controls. These results suggest that hypothermia given at
the same time as OGD as expected exerts a protective effect. In line with the
OGD experiments, for subsequent experiments primary cortical cultures were
exposed to a 6-hour period of OGD&hypothermia and then harvested
immediately for mRNA analysis.
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Fig 4-2. Time-course of OGD-induced LDH release in primary cortical
culture. 6 time points were selected and LDH was immediately measured
after OGD exposure. LDH release was significantly increased from
4-hour time point onwards compared to control. Values represent the
mean ± S.E.M, *p<0.05, **p<0.01, ***p<0.001, n=4 independent
experiments each performed in triplicate.
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Fig 4-3. Effect of recovery following 6-hour OGD on the extent of LDH
release. A 30-minute recovery period under normal conditions caused a
significant increase in LDH release compared to the non-recovery control
and this was further increased with longer recovery time. Values
represent the mean ± S.E.M, *p<0.05, **p<0.01, ***p<0.001. n=4












Fig 4-4. Time-course for LDH release induced by OGD&hypothermia.
There was no significant difference in TDH release between control
group and any time point of OGD&hypothermia exposure by 6 hours.
However, LDH release was significantly increased after 16-hour and
24-hour exposure to OGD&hypothermia compared to control group.
Values represent the mean ± S.E.M, **p<0.01, ***p<0.001. n=4
independent experiments, each performed in triplicate
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4.2.2 Effects of cellular stressors on MR variant mRNA levels in
primary cortical culture
RPA was used to detect the abundance of the three specific MR mRNA variants.
Specific riboprobes were targeted to each individual MR variant exon 1 and
complementary to the first 180 nucleotides of exon 2 (common to all MR mRNA
variants). This overlapped incorporation of exon 2 enabled total MR mRNA to be
measured simultaneously. Typically as shown in Fig 4-5 each sample contained a
band representing the individual MR variant (MRa expected protected fragment
size = 400nt; MRP = 206nt; MRy = 300nt) and a band representing the exon 2
overlap of MR (expected protected fragment size 180nt). The abundance of each
protected fragment was quantified by densitometric analysis (Fig 4-5) and the
absolute amount of total MR was calculated from the sum of the individual variant
and the exon 2 band. The house-keeping gene P-actin served as the internal
control (fragment size = 120nt). The transcript levels of each MR variant and total
MR were expressed relative to P-actin to assess the absolute difference between
treatment and vehicle group.
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Fig 4-5. Schematic illustration of each riboprobe designed to target
individual MR variant and total MR(A) and a representative
autoradiographic image of an RPA gel in a pilot experiment (B). The
RNA samples were extracted from rat primary cortical culture and
performed in duplicate for individual riboprobe.
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4.2.2.1 Proportion ofMR variant in total MR in primary cortical culture
Under normal conditions, all three MR mRNA variants were detected in primary
cortical culture by RPA with the MR(J> the predominant MR variant while MRa
and MRy were expressed to a lower extent. The proportion of each individual MR
variant calculated from all experiments showed MRp to be the most highly
expressed making up 56.55%±1.57% of the total amount of MR (a, (3 and y),
followed by MRy at 20.15%±2.35% and MRa at 15.24%±0.8%.
4.2.2.2 Effect of cellular stressors on MR variants
Results showed that none of the three MR transcript levels were significantly
altered in response to lOnM staurosporine (Fig 4-6A), 6-hour OGD (Fig 4-7A) or
6-hour hypothermia (Fig 4-8A) compared to the control group. However, 6-hour
OGD&hypothermia significantly increased MRP expression by 56%±8.8%
(p<0.05), whilst having no effect on either MRa or MRy (Fig 4-9B).
4.2.2.3 Effects of cellular stressors on total MR expression
Although 6-hour OGD&hypothermia significantly increased MRP transcript level,
total MR was not altered in response to this cellular stressor (p=0.07) (Fig 4-9C).
Exposure to the other three cellular stressors staurosporine(Fig4-6B), 6-hour OGD
(Fig 4-7B) or 6-hour hypothermia (Fig 4-8B) did not cause a significant increase




Fig 4-6. Quantitation of the effect of staurosporine on the expression of
MR variants in primary cortical culture. The staurosporine-treatment
group was expressed as a percentage of the vehicle group after
normalization by internal control P-actin (A). The effect of staurosporine
on total MR expression was also measured (B). lOnM staurosporine did
not alter the expression of either MR variants or total MR. Values





Fig 4-7. Quantitation of the effect of 6-hour OGD on the expression of
MR variants in primary cortical culture. The OGD-treatment group was
expressed as a percentage of the control group after normalization by
internal control P-actin(A). The effect of OGD on total MR expression
was also measured (B). 6-hour exposure to OGD did not alter the
expression of either MR variants or total MR. Values represent the mean




Fig 4-8. Quantitation of the effect of 6-hour hypothermia on the
expression ofMR variants in primary cortical culture. The hypothermia
treatment group was expressed as a percentage of the normothermia
group after normalization by p-actin(A). The effect of hypothermia on
total MR expression was also measured(B). 6-hour exposure to
hypothermia did not alter the expression of either MR variants or total
MR. Values represent the mean ± S.E.M, n=4-6 independent
experiments, each performed in triplicate.
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Fig 4-9. Quantitation of the effect of 6-hour OGD&hypothermia on the
expression of MR variants in primary cortical culture. The treatment
group was expressed as a percentage of the control group after
normalization by internal control P-actin(A). The effect of
OGD&hypothermia on total MR expression was also measured (B).
6-hour OGD&hypothermia significantly increased MRP variant
expression (p<0.05) while had no effects on MRa or MRy. Total MR
showed a tread to be increased in response to 6-hour OGD&hypothermia
(p=0.07). Values represent the mean ± S.E.M, *p<0.05, n=6 independent
experiments, each performed in triplicate.
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4.3 Discussion
In this chapter, the effects of different types of cell stress on the transcript levels of
each MR variant and of total MR were investigated in the primary cortical culture.
Findings are summarized in Tab 4-1.
Table 4-1 Summary of transcript levels of MRa, MRp and MRy in
response to different types of cellular stress in primary cortical culture
MRa MRp MRy Total MR
Staurosporine -*-►
OGD •4-*- •4-4-
Hypothermia <-*■ •4-4- ■4-4-
OGD&hypothermia t <-+■ •o-
-«-► no change; f significant increase
The data in chapter 3 provided a clue that both MRa and MR(3 transcripts can be
potentially induced in response to OGD&hypothermia, since their promoter
activities were significantly increased in differentiated PC 12 cells. However,
measurement of transcript levels in primary cortical culture after 6-hour
OGD&hypothermia showed only expression of MRP but not MRa was
augmented, whilst other stressors had no effects on any of the MR variants.
Clearly, this demonstrates and further verifies that (i) there is indeed a differential
induction of MR variant mRNA expression, (ii) this induction is confined
specifically to OGD&hypothermia.
Hypothermia is known to be neuroprotective, (Busto et al. 1989; Buchan et al.
1990; Baker et al. 1995), and this was verified in this system when measuring the
extent of cell damage (LDH release) in primary cultures exposed to OGD and
OGD&hypothermia (4.2.1.2 OGD&hypothermia). There was no measurable
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change in LDH release in OGD&hypothermia treated cells over several time
points up to 6 hours compared to controls whereas OGD treated cells showed an
increase in LDH release over time, indicting that hypothermia exerts a protective
effect against OGD-induced damage. Although this experiment was performed in
an in vitro primary culture, the induction of MRP strongly indicated that it is the
primary sensor involved in such an event. This may be due to the intrinsic
property of MRP, which has been already indicated to be involved in
neurodevelopment in the embryonic hippocampus (Vazquez et al. 1998). Given
the notion that the brain injury often triggers the cellular activities recapitulating
the events that underlie development (Chen et al. 2005), it is plausible that the
induction of MRp is predominantly responsive to injury. Furthermore, MRP was a
principle variant in total MR in primary cortical culture occupying over 50% MR
mRNA. This was partially in agreement with previous findings that this variant
was highly expressed in the developing hippocampus (Vazquez et al. 1998). Taken
together, MRp is an essential variant which acts as the primary transcript
responsive to injury through the activation of its own promoter. This discovery
sheds light on the development of an MR-based neuroprotective drug specifically
in neurons where MRp can act as a potential target.
The expression of total MR was not affected by any of the cellular stressors in
primary cortical culture. However, there was a trend that exposure to 6-hour
OGD&hypothermia caused an increase in the expression of total MR (p=0.07).
This was believed to be contributed by the increased MRP transcript solely. The
failure of induction of total MR may lie in the limited increased magnitude of
MRp, which was not enough to alter the total MR expression. Besides, the
calculation of total MR by sum of individual MR variant and exon 2 appears to be
an indirect method, which might also shields the true biological changes.
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Although MRa appears to be less abundant in primary cortical cultures than in the
adult brain in vivo, it is still an interesting target to explore. In Chapter 3, the
promoter activity of MRa was significantly increased after exposure to
OGD&hypothermia in differentiated PC12 cells, which implied a potential
increase in transcript level. Surprisingly the mRNA level of MRa in primary
cortical culture did not confirm such hypothesis. This discrepancy may be
explained by the fact that RNA was extracted immediately after exposure to
OGD&hypothermia. This may mask the potential change of MRa expression
since rates of transcription vary between genes and the time at which the change in
MRa expression may not have been captured. For the promoter experiments all
analysis was performed after 24 hours to maximize luciferase synthesis and steady
state levels. Secondly, the stability of MRa mRNA also needs to be considered
(Mignone et al. 2002) particularly if its half life is less than 6 hours. A protocol
which measures actual change in the rate of transcription of MR variant
expression may elucidate if expression is altered by OGD&hypothermia.
It has been shown that lOnM staurosporine addition for 1 hour in primary
hippocampal and cortical cultures caused an induction of MR abundance
(Macleod et al. 2003). The promoter study showed MRa promoter activity was
significantly increased by lOnM staurosporine regardless of PC12 cell phenotypes,
making it a strong candidate responsible for the induction of MR. Surprisingly,
staurosporine failed to induce the mRNA level in primary culture. Notably, the
variables between experiments may be too big to reach a statistical significance,
probably shielding the true biological effects of staurosporine. Therefore, it may
be worth trying an alternative method such as real-time PCR or semi-quantitative
PCR to measure the MRa expression directly.
The results form both chapter 3 and 4 demonstrate that the MRy variant is not
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affected by any of the cellular stressors in vitro, either at the promoter or mRNA
level. In primary cortical culture, it occupied approximately 20% of total mRNA,
even higher than MRa, but what its cellular role is remains to be elucidated.
In this study, recovery was excluded following OGD, hypothermia or
OGD&hypothermia in contrast to the promoter activity experiments in Chapter 3
due to high proportion of cell damage even for a minimum period. It is known that
restoration of circulation in global cerebral ischaemia leads to delayed neuronal
death in some vulnerable regions in the brain which may occur hours to days after
the insult (Pulsinelli et al. 1979; Kirino 1982; Pulsinelli et al. 1982). Although
increased OGD&hypothermia in primary cortical culture, the induction of MRP
could be prompt that only lasted a few hours and disappeared quickly when the
recovery was restored. Alternatively, the other two MR variants MRa and MRy
may also mount a late induction.
4.4 Concluding marks
This chapter provides evidence for specific transcriptional regulation of the MR
gene by OGD&hypothermia in primary cortical cultures. The data shows that
OGD&hypothermia significantly increases the MRp variant and demonstrates a
novel role for MRP in the response to injury. This suggests that targeting MRp in
neurons may be a way of treating neuronal injury. However, these observations are
based on in vitro experiments and to be of biological or clinical relevance, this
phenomenon needs to be verified in an in vivo system.
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Chapter 5
MESSENGER RNA LEVELS OF THE MINERALOCORTICOID
RECEPTOR VARIANTS IN HYPOTHERMIC ANOXIA
NEONATAL RAT
5.1 Introduction
The work in chapter 3 and chapter 4 has identified that MR(3 variant is the primary
sensor responsive to the cellular injury. Although the in vitro studies provide a
good initial screen for the differential regulation of MR, there are still several
limitations in particular they do not reflect the actual physiological environment
where the neurons reside and exert their functions. For example, substantial less
glia cells are present in primary cortical culture in comparison to the brain in vivo
and the architecture of the cerebral cortex is completely disrupted that may cause
altered intracellular communication and activities. More crucially, it is not known
whether the cell culture itself has an impact on the gene expression in the cells
because the change of the environment will certainly be considered as a "stressful"
event that might disrupt the cellular homeostasis and subsequently lead to a series
of cellular responses. Therefore, to validate the changes in the expression profiles
of the MR variant mRNA transcripts in vitro and of biological importance, this
chapter will examine the transcription regulation of MR in in vivo models.
Unfortunately the adult rat hypothermic global ischaemia model where previous
work was carried out is not available, the work was carried out in a well
characterized cerebral anoxic neonatal rat model where the body temperature can
be easily manipulated (Caputa et al. 2001).
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Cerebral hypoxia remains a major health problem for infant and children that can
induce chronic neurological dysfunction throughout their lifespan, including
impaired learning and memory, cerebral palsy, mental retardation and epilepsy
(Buwalda et al. 1995; Vannucci et al. 1997; Fan et al. 2005). It is defined as partial
or complete lack of oxygen supply to the brain due to obstructed airways or
cut-off of the atmospheric oxygen. Severe hypoxia is referred to as anoxia which
can cause irreversible pathological changes and neuronal loss in brain regions
particularly those vulnerable to oxygen shortage such as the hippocampus (Nyakas
et al. 1996; Oechmichen et al. 2006). At the cellular level, anoxia shares the
similar pathophysiological process with cerebral ischaemia, including ion
disturbances, Ca2+ overload, formation of oxidative free radicals and apoptosis
(Vannucci 1990; Johnston et al. 2001). In addition, a variety of studies showed the
endogenous survival factors are also mounted in this type of animal models
(Vexler et al. 2001).
In hypothermic anoxia neonatal rat models, changes in the expression of MR
variant transcripts were measured specifically in the hippocampus since (i)MR is
predominantly expressed in this part of the brain and (ii)the hippocampus is
particular vulnerable to the damaging effects of ischaemia. The aims of this
chapter were specifically to investigate:
(i) If MR gene expression is induced in hypothermic anoxic neonatal rats.
(ii) Which MR variant(s) is/are responsible for the induction of total MR in
this animal model.
5.2 Results
The abundance of total MR was measured by in situ hybridization using 513nt
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cRNA riboprobe targeting the 3'-untranslated region which was reported in
previous study (Yau et al. 1994). For the detection of individual MR variant,
another three cRNA riboprobes were synthesized and specifically complementary
to the entire MRa, MR|3 and MRy exonl region, thereby ensuring the specificity
for each receptor variant. Quantification was carried out using silver grain counts,
which is expressed as the ratio of total grey levels relative to number of
radioactive hybrids per neuron.
5.2.1 Basal distribution pattern in hippocampus
Grain counting analysis showed that under normal conditions, total MR was most
enriched in CA3 subfield while least abundant in CA4. The distribution of total
MR expression in hippocampal subfields from the highest level was
CA3>DG>CA2>CA1>CA4. The pattern was same as for the MR variants, only
with the exception that MR(3 and MRy had a higher expression in CA1 than CA2
(Tab 5-1).
5.2.2 Effect of hypothermic anoxia
As shown in Fig 5-2, in comparison to sham group, anoxia at normothermia did
not alter MR mRNA in any of hippocampal subfields by one-way ANOVA
analysis. However, anoxia&hypothermia caused a significant increase in
hippocampal MR expression by 119.5% in CA1 (p<0.05), 46.68% in CA2,
(p<0.05), 48.36% in CA3 (p<0.05), 89.24% in CA4 (p<0.001) and 46.91% in DG
(p<0.05). In addition, hypothermia alone was also associated with increased MR
mRNA expression in all hippocampal subfields except CA2 (p=0.052).
Subsequently, the transcript level of each of MR variants was tested using the
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specific cRNA riboprobe. Neither MRa (Fig 5-4) nor MRy (Fig 5-8) mRNA levels
were significantly altered in response to any of the treatments in any of the
hippocampal subfields.
However, anoxia&hypothermia significantly increased MRP mRNA levels in
comparison to the sham group, by 54.78% in CA1 (p<0.05), 66.48% in CA2
(p<0.05), 42.56% in CA3 (p<0.01), 51.47% in CA4 (p<0.05) and 60.14% in DG
(p=0.001). The induction of MRP was also found in response to hypothermia
alone in hippocampal CA1 (by 128.6%, p<0.05), CA2 (by 51%, p<0.05), CA3 (by
66.67%, p<0.05), CA4 (by 74.06%, p<0.01) and DG (by 69.5%, p<0.05)
compared to the sham group. However, anoxia alone did not affect the expression
of MRp mRNA abundance in the hippocampus (Fig 5-6). This suggests the
induction of total MR expression was solely contributed by MRp.
5.2.3 Two-way ANOVA
A two-way ANOVA considering two factors of hypothermia and anoxia for each
cRNA probe versus the sham group was performed to evaluate their impact on the
transcript levels of each MR variant and total MR. The effect of hypothermia
alone was statistically significance in MRp (F 21.591; p<0.001) and total MR (F
5.696; p<0.05), but anoxia did not affect either of them (MRP: F 0.23, p=0.63;
total MR: F 0.34, p=0.56). The interaction between hypothermia and anoxia did
not reach statistical significance for MRP (F 0.676; p=0.413) or total MR (F 1.889;
p=0.172), suggesting the induction ofMRp was purely rely on the hypothermia. In
addition, neither MRa nor MRy was affected by these two factors.
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A BCD
Fig 5-1. Representative pictures for total MR mRNA levels in
hypothermic anoxia neonatal rats. [Column (A)]: sham; [Column (B)]:





CA1 CA2 CA3 CA4 DG
Subfield
Fig 5-2. Effect of hypothermic anoxia on MR expression in neonatal
rats. MR expression was significantly increased in all of hippocampal
subfields by anoxia&hypothermia. Hypothermia alone also induced an
increase in MR expression in hippocampal CA1, CA3, CA4 and DG
subfields. Data represent mean ± S.E.M, *p<0.05; **p<0.01;
***p<o 001, n=6 animals per group with each performed in triplicate
brain sections.
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Fig 5-3. Representative pictures for MRa mRNA levels in hypothermic
anoxia neonatal rats. [Column (A)]: Sham; [Column (B)]: Anoxia;
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Fig 5-4. Effect of hypothermic anoxia on MRa expression in neonatal
rats. There was no significant difference in MRa expression between
treatment group and sham group in any of the hippocampal subfields.
Data represent mean ± S.E.M, n=6 animals per group with each
performed in triplicate brain sections.
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Fig 5-5. Representative pictures for MR(3 mRNA levels in hypothermic
anoxia neonatal rats. [Column (A)]: sham; [Column (B)]: Anoxia;
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Fig 5-6. Effect of hypothermic anoxia on MRp expression in neonatal
rats. MRP expression was significantly increased in all of hippcoampal
subfields in response to both hypothermia and anoxia&hypothermia
compared to sham group. Data represent mean ± S.E.M, *p<0.05;




Fig 5-7. Representative pictures for MRy mRNA levels in hypothermic
anoxia neonatal rats. [Column (A)]: sham; [Column (B)]: Anoxia;




CA1 CA2 CA3 CA4 DG
Subfield
Fig 5-8. Effect of hypothermic anoxia on MRy expression in neonatal
rats. There was no significant difference in MRy expression between
treatment group and sham group in any of the hippocampal subfields.
Data represent mean ± S.E.M, n=6 animals per group with each
performed in triplicate brain sections.
168
Table 5-1 Effect of anoxia and hypothermia on expression ofMR and variants
in neonatal rat
Control Anoxia
MR Normothermia Hypothermia Normothermia Hypothermia
CA1 25.49 ±4.36 58.27 ±9.17a 38.99 ±7.16 55.95 ±8.26a
CA2 29.61 ±4.1 48.43 ± 6.85 38.64 ±6.11 43.43 ± 2.82a
CA3 94.23 ± 8.23 157.05 ± 16.87a 132.74 ±7.66 139.74 ± 10.81b
CA4 14.51 ±0.72 25.26 ±2.2b 22.03 ± 2.72 27.46 ± 1.89c
DG 49.19 ±5.73 83.38 ±9.53a 63.57 ±5.87 72.27 ±7.38a
MRa
CAl 26.75 ± 3.03 23.3 ±2.31 26.59 ± 1.97 26.44 ± 1.74
CA2 27.32 ±3.39 27.08 ±2.17 29.56 ±3.22 27.21 ± 1.60
CA3 67.21 ±5.47 67.53 ± 4.54 67.94 ±4.50 68.33 ±3.56
CA4 18.14 ±2.42 16.98 ± 1.35 17.14 ± 1.15 18.02 ± 1.04
DG 30.97 ±3.88 30.20 ±2.12 32.34 ± 1.93 31.81 ± 1.99
MRp
CAl 53.68 ±7.57 76.11 ±2.82a 50.71 ±5.58 83.08 ±7.28a
CA2 51.83 ±8.22 78.27 ±2.77a 51.61 ±5.05 86.29 ±8.34a
CA3 112.64 ±8.65 155.25 ± 10.52a 111.02 ±7.59 160.58 ±8.74b
CA4 32.56 ±3.12 45.44 ± 1.73b 29.55 ± 2.22 49.32 ± 6.44a
DG 79.18 ±5.77 106.18 ±6.44a 75.38 ±5.75 126.79 ±9.14b
MRy
CAl 15.27 ± 1.61 15.45 ± 1.44 16.55 ± 1.97 16.18 ±0.75
CA2 14.17 ± 1.83 15.04 ± 1.60 14.53 ± 1.27 17.19 ± 1.67
CA3 23.51 ±2.78 27.95 ± 3.05 24.01 ±2.34 29.45 ± 1.90
CA4 12.88 ± 1.10 13.72 ± 1.39 14.82 ±0.85 15.47 ±0.77
DG 19.37 ± 1.44 21.18 ± 1.26 21.67 ± 1.76 21.85 ± 1.41
aP<0.05 vs normothermia control; bP<0.01 vs normothermia control;
CP<0.001 vs normothermia control. One-way ANOVApost hoc test.
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5.3 Discussion
The data in this chapter demonstrated that MR gene expression was differentially
regulated in hypothermic anoxic neonatal rats in vivo. This was the last model
system used in this project and the results were summarized in Tab 5-1.
In chapter 4, only MR(3 mRNA level was significantly increased in response to
OGD&hypothermia in primary cortical culture but failed to induce an increase in
total MR expression. This in vitro study suggested that MRfl was the primary
spliced variant involved in hypothermic neuroprotection following ischaemic
insult. However, the question remains on whether this is of biological relevance in
in vivo animal models. The results in this chapter confirmed the findings in
chapter 4, that MR(3 was indeed the sole variant responsible for the induction of
total MR in response to hypothermic anoxia, establishing the important role of
MR(3 in mediating MR-based neuroprotection. In adult rats, increased MR gene
expression was limited to CA3 and CA4 subfields by hypothermic transient global
ischaemia (Macleod et al. 2003), whereas the induction of MR was found in all
hippocampal subfields in neonatal rat treated with hypothermic anoxia. The
difference was probably attributable to the different transcript levels of MR(3
between neonatal and adult rats. Vazquez reported MR(3 was highly expressed in
the developing hippocampus but declined in adults (Vazquez et al. 1998). In
primary cortical culture, MRp was a predominant variant occupying over 50% of
total MR (4.2.2.1). Therefore, it is assumed that inadequate expression of MRP in
adult rats compared to newborn animals may not be able to induce an overall
increase in MR abundance in response to hypothermic ischaemia in hippocampal
CA1, CA2 or DG. This hypothesis can be validated by performing the same
experiments to measure the expression of each MR variant in hypothermic
ischaemic adult rats. In addition, this elicits an important clinical strategy to
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develop the potential therapeutic interventions based on enhancing MR expression
in which MRP can be a primary target.
Surprisingly, two-way ANOVA considering the two factors, hypothermia and
anoxia, indicated that hypothermia was a significant factor involved in the
expression of total MR in vivo. Post hoc analysis demonstrated that hypothermia
alone augmented the expression of total MR in hippocampal subfields except CA2.
Currently there are very few reports available correlating MR expression to the
temperature in the central nervous system. Sun demonstrated that the temperature
at 26°C can significantly increase the mRNA and protein levels of MR in heart,
kidneys and hypothalamus in mice compared to the normothermic condition (Sun
et al. 2008). The mechanism of the induction in these tissues was assumed to be
the role of MR in mediating blood pressure. At hypothalamus level, MR induction
was independent from the circulating concentration of aldosterone, suggesting
other mechanisms than autoregulation may direct the expression of MR at lower
temperature (Sun et al. 2008). Coincidently, the data in this chapter demonstrated
that hippocampal MR expression was also subjected to such thermal regulation in
neonatal rat and this was believed to be mediated by MRP variant solely. The
mechanism by which MRp is subjected to thermal regulation in the hippocampus
has not been reported, but it might be related to the developing brain, since
hypothermia treatment in adult rat did not change MR abundance in any of
hippocampal subfields (Macleod et al. 2003). Another reason may be the less
severity of the anoxic insult in this neonatal model which was not enough to
mount an MR-mediated survival response. The brain of a newborn animal is
believed to be more resistant to a hypoxic/anoxic insult in contrast to the adults
(Cherubini et al. 1989; Haddad et al. 1990). A quick examination of stained
neonatal brain sections post-anoxia revealed an absence of neuronal damage in
contrast to the adult rat (Macleod et al. 2003). Previous studies have shown that
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immature neurons demanded less energy input at the developmental stage i.e.
lower levels of neurotransmitter synthesis and glucose utilization (Vannucci et al.
1989; Nehlig et al. 1993; Krajnc et al. 1994). Furthermore, the neonatal rats
maintained their core temperature at 32-33°C under normal conditions (Bertin et
al. 1993; Caputa et al. 2001), which is the hypothermic condition for the adult rat
and presumed to protect the neonatal developing neurons from anoxic insult. This
can be partially confirmed by the study using hyperthermia at 37°C and 39°C,
which significantly reduced the tolerance of neonatal rats in exposure to anoxia
(Rogalska et al. 2005). Therefore, lowered core temperature is beneficial for
resistance to anoxic insult.
In addition, it is note worth to mentioning GR may also play a fundamental role in
the induction of MR. Hypothermia was associated with reduced GR mRNA levels
compared to normothermic ischaemia in adult rats (Macleod et al. 2003),
suggesting a potential role for modulation of steroid receptors in response to
ischaemia. Gradually increased circulating steroid concentration would have a
greater impact on potentially neurotoxic GR signalling than on MR signalling, due
to relative lower affinity of steroids for GR (Reul et al. 1985). Hence, it is
assumed that increased MR may have evolved as a mechanism to enhance the MR
signalling to counteract GR-induced deteriorating effects (Macleod et al. 2003).
Our preliminary data in the same neonatal rat models using GR-specific riboprobe
demonstrated that (i) the transcript of GR was detectable in hippocampal CA1 and
CA2 but extremely low in the other three subfields (CA3, CA4 and DG) and (ii)
GR expression was not significantly altered by either hypothermia or
anoxia&hypothermia in comparison to sham groups in CA1 or CA2 subfield
(Appendix 5). This rules out the possibility that the increased MR expression was
attributable to decreased GR and suggests the up-regulation ofMR in hypothermic
anoxic neonatal rat may be subjected to injury-specific mechanisms irrespective of
GR.
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MRa variant was consistently expressed in the hippocampus from birth to adult
(Vazquez et al. 1998) and was responsive to corticosterone at promoter and
transcript levels in neurons (Castren et al. 1995). Although the promoter activity
was augmented by staurosporine and OGD&hypothermia, the transcript level of
MRa was not altered in either primary cortical culture in vitro or neonatal rats in
vivo, indicating this is not a primary sensor involved in the induction ofMR.
Although MRy is important in the neonatal rat with considerable expression in
developing hippocampus (Vazquez et al. 1998), the data suggested it was not a
primary factor in response to cellular stressors.
5.4 Concluding remarks
In this chapter, the transcript levels of total MR and the three variants in
hypothermic anoxic neonatal rats were measured. The data shows that both
hypothermia alone and anoxia&hypothermia caused a significant increase in the
expression of total MR in the hippocampus of neonatal rat, which is contributed
by the induction of MR(1 variant solely. This corroborates the findings in vitro that
MRP is indeed the predominant variant responsible for the induction of total MR
in hypothermic neuroprotection following cerebral ischaemic insult, being of
substantial importance for the development of potential MR-based neuroprotectant




It is well known that the essential function ofMR is not only limited to regulating
salt and water homeostasis in the kidney, but also linked to maintenance of
neuronal viability in the brain after exposure to various stressful conditions such
as cerebral ischaemia (Almeida et al. 2000; Macleod et al. 2003; Crochemore et al.
2005; Lai et al. 2007). This provides a novel strategy to develop the potential
neuroprotectants based on enhancing MR signalling specifically in the neurons in
conditions of ischaemic stroke or cardiac arrest.
However, how MR is regulated in such events is still unknown. Therefore, this
thesis aims to answer this question by examining the expression of MR variants
including promoter activity and mRNA abundance in three distinct systems ~ cell
line, primary cortical culture and in vivo animal models. The main findings are
summarized as below:
(i) There is indeed a differential regulation of MR in response to specific
cellular stressors.
(ii) MRP is the primary sensor responsible for the induction of MR in
hypothermic ischaemia in in vitro primary cortical culture and in vivo
neonatal rat.
(iii) The induction of MRp is initiated at promoter level.
The induction ofMR responsive to specific cellular stressors is mediated by MR/3
Alternative RNA splicing is originally believed to expand the diversity of protein
products from a single gene. Furthermore, it was later found that it can also
generate multiple mRNA species differing in the 5'-untranslated regions but
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encode the same protein, which is associated with a better control of gene
expression in different tissues, organic developmental stages and other cellular
activities (Graveley 2001). Subjected to such mechanism, rat MR gene gives rise
to three mRNA variants with different transcription patterns in tissues and
embryonic development (Patel et al. 1989; Kwak et al. 1993). Our group found
that MR abundance was induced in rat primary cortical cultures by staurosporine
treatment in vitro and hippocampus by hypothermic transient global ischaemia in
vivo (Macleod et al. 2003), raising a novel mechanism that may also participate in
the expression of endogenous MR.
The data demonstrate that the transcript levels of MR variants are differentially
regulated in response to the cellular stressors and MRP is verified to be the
primary sensor specifically in hypothermic neuroprotection following ischaemic
insults both in vitro and in vivo. This differential regulation of transcription in the
context of brain injury is not unique to MR, for example, the neurotrophic factor
BDNF gene gives rise to four mRNA variants each under the control of its own
promoter, in a same manner as MR. Besides, the BDNF mRNA variants manifest
distinct expression patterns in exposure to cerebral ischaemia in vivo (Tsukahara et
al. 1998).
Currently, there is little information on the transcription regulation of MRP variant
in the rat. The expression of MRP was barely detected in the kidney but share
approximately same proportion with MRa in the adult rat hippocampus (Kwak et
al. 1993). The abundance of MRP was enriched in hippocampus during embryonic
foetal development but declined rapidly in adult (Vazquez et al. 1998). The study
in Chapter 4 also demonstrated that MRp occupies over 50% of total MR
transcripts in primary cortical culture, confirming it is a predominant variant in the
young animals.
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The mechanism of MR(3 induction is not clear, but it might involve the cellular
responses to brain injury that underlies the development (Chen et al. 2005). Given
the role of MR(3 in neuronal development, it is plausible to hypothesize that the
induction of MR(3 is responsive to such events. Surprisingly, hypothermia alone
also up-regulated MR|3 expression in neonatal rat in vivo which consequently
leads to the induction of total MR. This might be due to either less sensitivity of
neonatal rats in response to anoxia or inadequate severity of insult that is not
enough to mount an MR-mediated survival response eventually.
More importantly, it appears that the induction MR(3 expression is only confined
to neuronal cells and responsive to neuronal injuries. This is supported by the
findings that the increased MRp promoter activity was found in neuronal-like
differentiated PC12 cells and the transcript levels were up-regulated in primary
cortical culture and brain hippocampus. It is a vital discovery for the future
development of potential MR-based neuroprotectant, since the activation of MR in
other tissues in particular heart and cerebral vessels could bring severe damage
following cerebral ischaemia (Dorrance et al. 2006; Zhang et al. 2008). Further
experiments testing MR(3 expression in these tissues outside brain in response to
the same cellular stressors are necessary to rule out the possible involvement of
MR(3.
The induction ofMR/3 is initiated at thepromoter level
Previous study has shown MR is nearly saturated at basal level of circulating
corticosteroids in the brain (Reul et al. 1987). Therefore, the induction of MR
signalling relies on an increase in the receptor availability instead of hormone
level and this is believed to be initiated at gene transcription level. Assays of
luciferase reporter gene under the direction of 300bp MR(3 promoter fragment
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demonstrated the promoter activity was significantly increased in response to
OGD&hypothermia in neuronal-like differentiated PC12 cells in vitro, suggesting
the induction of MRp is initiated at the promoter level.
Probably due to lack of enhancers within such a short region, basal promoter
activity of MR(3 is lowest of three MR variants. To examine if the necessary
element(s) responsible for the increased promoter activity in exposure to
OGD&hypothermia is/are exclusively located in this 300bp region, two longer
extension promoter constructs were generated and subjected to the same cellular
stressor OGD&hypothermia using the same method as the experiments in Chapter
3 (Please refer to appendix 3). The basal promoter activity was significantly
increased whereas the magnitude of induction by OGD&hypothermia was not
changed between them, suggesting the potential element(s) is/and located within
the first 300bp promoter region.
Elk-1 is a potential transcription factor responsible for MR(5 induction
Our group has reported an association between increased MR mRNA and
activation of the ERK pathway in primary neuronal cultures which were subjected
to cell stress staurosporine (Macleod et al. 2003). Data using a variety of protein
inhibitors or blockers demonstrated that inhibition of ERK pathway, can
significantly attenuate OGD&hypothermia-induced MR(3 promoter activity (Peng
et al. in press), suggesting a potential involvement of ERK. Screening of 300bp
MRp promoter region reveals a putative transcription factor binding site for Elk-1,
a downstream effector in ERK pathway.
Elk-1, a member of ternary complex family of ETS-related transcription factor, is
fundamentally important for cellular proliferation, differentiation, development
and transformation (Sharrocks 2001; Oikawa et al. 2003). In central nervous
system, Elk-1 gene is strongly expressed in the brain and restricted in neuronal
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cells (Janknecht et al. 1994; Pingoud et al. 1994; Price et al. 1995).
Stress-inducing multiple factors in MARK pathways like ERK, JNK and p38 are
able to activate Elk-1 by phosphorylation (Janknecht et al. 1994; Cavigelli et al.
1995; Gille et al. 1995; Enslen et al. 1998; Ferrer et al. 2001). Particularly the
phosphorylated Elk-1 was up-regulated in hypoxia model in vitro (Muller et al.
1997) and later was reported in animal models in both focal and cerebral
ischaemia (Wang et al. 2004; Krupinski et al. 2005). Indirect evidence comes from
the coincidence of hypothermic neuroprotection with the activation of ERK
pathway (Hicks et al. 2000; D'Cruz et al. 2002), which possibly act through Elk-1.
Taken together, it strongly suggested that activation of Elk-1 induces MRp
expression but further experiments using promoter deletion constructs, DNase
footprinting and EMSA are necessary for the validation of this hypothesis.
MRa is not a sensor although the promoter is increased
During foetal development, MRa was consistently expressed at a lower level in
comparison to MR(J in the hippocampus (Vazquez et al. 1998). However, in adult
rat MRa is the predominant variant in kidney and shares a same proportion with
MR(1 at approximately 30% in the hippocampus (Kwak et al. 1993). The basal
promoter activity is significantly higher than MR|3 and MRy in both
undifferentiated and differentiated PC12 cells, suggesting it is a fairly active
variant in terms of transcriptional activity. Both staurosporine and
OGD&hypothermia caused an increase in MRa promoter activity in PC12 cells,
the transcript levels were not altered in the model systems either in vitro or in vivo.
This is probably due to the intrinsic properties of MRa variant such as mRNA
stability and degradation rate, or the RNA processing like post-transcriptional
modification.
Up-regulation ofMRP — a role in aging animals?
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In neonatal rats, the up-regulation of MR(3 in exposure to OGD&hypothermia was
found in hippocampus over the five subfields, accounting for the induction of total
MR. Given the notion that there is a highly homology in pathophysiology between
cerebral ischaemia and cerebral anoxia in animal models (Vannucci 1990;
Johnston et al. 2001), this is of clinical relevance because the condition here
mimicks the hypothermic treatment for the ischaemic patients. Therefore, specific
stimulation of MRP expression can act as an effective endogenous factor which
initiates the survival signalling in a same manner as hypothermia to protect the
neurons from death.
However, epidemiological study on human cerebral ischaemia demonstrated that
the vast majority of ischaemic episodes occurring in those aged >65 years (Sudlow
et al. 1997; Wolfe 2000). Substantial loss of neurons and altered cellular activities
are exclusively present in the aging brain (Crain et al. 1988). Besides, pre-clinical
research also reported that aged animals are more vulnerable to ischaemic insult
and may lack the sensitivity to the treatment, probably due to reduced energy
utilization, accumulation of oxidation and increased GC levels (Xu et al. 2007).
Besides, the expression of hippocampal MR in aged animals was significantly
reduced in comparison to adult (Sapolsky et al. 1983; Reul et al. 1988), which
may account for loss of neurons as well. Taken together, this might compromise
the potential changes of MRP expression due to lack of efficient endogenous
survival mechanisms that can switch on MRp. An exploration on the transcript
levels of MR variants in aged animals in exposure to hypothermic cerebral
ischaemia would certainly be helpful towards the thorough understanding of
transcription regulation of MR.
In comparison to previous neuroprotectants examined in pre-clinical research, MR
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has several unique advantages, (i) As a transcriptional factor, MR is known to
regulate a number of genes downstream including up-regulating anti-apoptotic
genes Bcl-2 and Bcl-xl (Almeida et al. 2000; McCullers et al. 2001), neurotrophic
factors such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3
(NT3) (Hansson et al. 2000) and down-regulating NMDA receptor expression
(Nair et al. 1998). There can effectively trigger a number of efferent effects to
promote neuronal survival, (ii) MR is an endogenous survival factor which may be
involved in hypothermic neuroprotection. Hypothermia is well known for its
neuroprotective role and has been widely used in clinical treatment for stroke
patients. However, there are some limitations to the utilization of such intervention
including side-effects and optimizing conditions for every patient (General
introduction 1.2.5.2). Since hypothermia induced the expression of MR in
transient global ischemia in vivo (Macleod et al. 2003), the neuroprotection of MR
may share the same mechanism with hypothermia. Thus enhancing MR signalling
can be a more potent target to exert the hypothermic protective effects, (iii)
Human or rat MR gene gives rise to multiple mRNA transcripts which have
distinct transcriptional expression pattern in different tissues or developmental
stages (Kwak et al. 1993; Zennaro et al. 1995; Zennaro et al. 1997; Vazquez et al.
1998). In addition, this thesis demonstrated that these transcripts are also
differentially regulated in an injury-specific manner. Hence, MR gene expression
can be up-regulated specifically in neurons in response to cerebral ischemic insult,
avoiding the potential deleterious effects caused by MR activation in other tissues
such as vascular system.
In this thesis, the transcription regulation of MR variants in exposure to different
types of cellular stress was investigated. The promoter activity, mRNA levels were
measured for each of MR variants in in vitro and in vivo ischaemic models. MR(1
was identified as a primary effector involved in hypothermic neuroprotection
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during cerebral ischaemic-hypoxic damage. Therefore, up-regulation of MR(f
variant specifically in the neurons can serve as a novel and suitable target for
future development of neuroprotective drug to enhance the MR-mediated survival
signalling.
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Appendix 1: Generation of neonatal rat anoxia
Neonatal brains exposed to hypothermic anoxia were generated through a
collaboration with Dr. Justyna Rogalska, N. Copernicus University, Torun Poland
(Caputa et al. 2001).
Briefly, 2-day old Wistar rat pups weighing 7-8g were placed in temperature
controlled plethysmographic chambers either at 33°C (normal body temperature of
neonatal rats) or 31°C (hypothermia). Rectal temperature was recorded and as
soon as the desired body temperature was reached, anoxia was elicited to the
animals by flushing 100% nitrogen into the chambers. Respiratory efforts (gasping
movements) were continuously recorded throughout the experiments using the
barometric method. Animals were maintained were maintained under anoxic
conditions for 25 minutes. After anoxia, animals were exposed to atmospheric air
at unchanged temperature for 120 minutes then sacrificed. Brains were dissected
and immediately frozen on dry ice. Control rats were placed in chambers and
exposed to atmospheric air for the same period of time (145 minutes) under the
respective temperature conditions.
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Appendix 2: Measurement of cell death by LDH assay
The percentage of cell damage was calculated according to the following
equation:
PrelysisfLDH]
Death percentage (%)= x 100
(1) Total [LDH]
Total [LDH] = New released [LDH] + prelysis[LDH] 1
Because the addition of 50ul of medium will dilute the current LDH before cell
lysis occurs by a factor of 150/200, the postlysis [LDH] can not be recognized
simply as the Total [LDH], but
Measured [LDH]=Newly released [LDH] + 150/200 prelysis [LDH] 2
Therefore,
Newly released LDH= Measured[LDH] - 150/200 prelysis [LDH] 3
Ifwe substitute the newly released[LDH] in equation 1 with the one in 3, then.
Total [LDH]= Measured[LDH] - 150/200 prelysis[LDH] + prelysis[LDH]
=Measured[LDH] + 1/4 prelysis[LDH]
Finally, we got
Prelysis[LDH]
Death percentage (%)= x 100
Meaured[LDH] + 1/4 prelysis[LDH]
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Appendix 3: Promoter activity of pMRp extension
constructs in response to OGD&hypothermia in
undifferentiated and differentiated PC12 cells
To validate the increased promoter activity of MP[3 after exposure to
OGD&hypothermia was mediated by its unique 300bp promoter region, two
longer promoter fragments, pB2100 with a length of 2.1kb and pB436 with 436bp,
were individually amplified from rat genomic DNA and sub-cloned into pGL-3
vector. The method was same as stated using transient transfection into
undifferentiated and differentiated PC12 cells in response to OGD&hypothermia.
In both undifferentiated and differentiated PC12 cells, the longest construct
pB2100 showed the highest basal promoter activity, while pB436 activity was
lower than pB2100 but higher than the original pB300. OGD&hypothermia did
not increase the promoter activity of pB2100, pB436 or pB300 in undifferentiated
PC12 cells. However, in differentiated PC12 cells, the promoter activity was
significantly increased from 2.96 to 3.55 for pB2100 (120%± 3.3%, p<0.05), 1.04
to 1.58 fold for pB436 (150%± 13%, p<0.05) and 0.69 to 0.96 fold for pB300
(138%±6.6% p<0.05).
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Promoter activity of MRP extension constructs in response to
OGD&hypothermia in undifferentiated (A) and differentiated (B) PC 12
cells. None of MR(3 constructs were significantly altered by
OGD&hypothermia in undifferentiated cells, whereas they were
significantly increased in differentiated cells. *p<0.05, Mean + S.E.M, n=5
independent experiments each performed in triplicate.
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Expression of MR and its variants in hippocampus in hypothermic anoxic
neonatal rat. Column A: sham; Column B: anoxia; Column C: hypothermia;
Column D: anoxia&hypothermia; Column E: sense
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Appendix 5: Effect of hypothermic anoxia on GR


















Effect of hypothermic anoxia on GR expression in neornatl rat. There
was no significant difference in GR expression between treatment
group and sham group in any of the hippocampal subfield. Data
represent mean ± S.E.M, n=6 animals per group with each performed
in triplicate brain sections.
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